3URGXFW'DUEHSRHWLQDOID
3URWRFRO1XPEHU
'DWH'HFHPEHU 3DJHRI
7LWOH67$57&.'6WUDWHJLHV8VLQJ'DUEHSRHWLQDOIDWR$YRLG7 UDQVIXVLRQVLQ
&KURQLF.LGQH\'LVHDVH
$PJHQ3URWRFRO1XPEHU'DUEHSRHWLQDOID
&OLQLFDO6WXG\6SRQVRU $PJHQ,QF
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV&$
7HO
)D[
.H\6SRQVRU&RQWDFWV
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV&$
'DWH
$PHQGPHQW
$PHQGPHQW
$PHQGPHQW0DUFK
$SULO
-XQH
'HFHPEHU
&RQILGHQWLDOLW\1RWLFH
7KLVGRFXPHQWFRQWDLQVFRQILGHQWLDOLQIRUPDWLRQRI$PJHQ,QF
7KLVGRFXPHQWPXVWQRWEHGLVFORVHGWRDQ\RQHRWKHUWKDQWKHVW XG\VWDIIDQGPHPEHUV
RIWKHLQVWLWXWLRQDOUHYLHZERDUG
7KHLQIRUPDWLRQLQWKLVGRFXPHQWFDQQRWEHXVHGIRUDQ\SXUSRVH RWKHUWKDQWKH
HYDOXDWLRQRUFRQGXFWRIWKHFOLQLFDOLQYHVWLJDWLRQZLWKRXWWKH SULRUZULWWHQFRQVHQWRI
$PJHQ,QF 
,I\RXKDYHTXHVWLRQVUHJDUGLQJKRZWKLVGRFXPHQWPD\EHXVHGR UVKDUHGFDOOWKH
$PJHQ0HGLFDO,QIRUPDWLRQQXPEHU$0*(1 )RUDOORWKHUVWXG\UHODWHG
TXHVWLRQVFRQWLQXHWRFRQWDFWWKH.H\6SRQVRU&RQWDFW[COMPANY_003]
[COMPANY_003]
1&71XPEHU
7KLV1&7QXPEHUKDVEHHQDSSOLHGWRWKHGRFXPHQW
IRUSXUSRVHVRISRVWLQJRQFOLQLFDOWULDOV
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 2 of 67 
 Investigatorâ€™s Agreement  
I have read the attached protocol entitled START -CKD:  Strategies Using 
Darbepoetin alfa to Avoid T ransfusions in Chronic Kidney Disease, dated 
16 December  2013 and agree to abide by [CONTACT_3769].  
I agree to comply with the International Conference on Harmonisation Tripartite 
Guideline on Good Clinical Practice.  
I agree to ensure tha t Financial Disclosure Statements will be completed by:  
â€¢ me (including, if applicable, my spouse [or legal partner] and dependent children)  
â€¢ my subinvestigators (including, if applicable, their spouses [or legal partners] and 
dependent children)  
at the start  of the study and for up to [ADDRESS_1160261] of the clinical investigation 
without the prior written consent of [COMPANY_010] Inc . 
   
Signature    
[CONTACT_121365]   [CONTACT_1782] (DD Month YYYY)  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 3 of 67 
 The START -CKD study is designed to describe the benefits and potential risks of a ne w 
treatment strategy using a fixed dose of darbepoetin alfa in subjects with chronic kidney disease 
and not on dialysis  (ND- CKD) .  Subjects will be randomly allocated to treatment with a fixed dose 
of darbepoetin alfa or to treatment with darbepoetin alfa using a hemoglobin ( Hb)-based titration 
strategy, which has been the conventional dosing strategy.   This study  aims  to estimate t he 
incidence of red blood cell ( RBC ) transfusions  (administered as deemed clinically necessary)  in 
each group and the differenc e in incidence of RBC transfusions between the [ADDRESS_1160262] s, such as cumulative darbepoetin alfa dose, total number of units of 
transfusions, Hb concentration, Hb- related parameters (eg, Hb variability, excursions, rate of 
change), and adverse (eg, cardiovascular ) events , will also be considered in order to determine a 
preferred dosing regimen. 
Protocol Synopsis  
Title:   START -CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic Kidney 
Disease  
Study Phase:   3 
Indication:  Management of anemia in chronic kidney disease patients not on dialysis.  
Primary Objective:   To evaluate the incidence of RBC transfusions in ND -CKD  subjects  using 
either a Hb- based titration algorithm or a weight -based dose that will not be tit rated (fixed dose), 
and to evaluate the difference in the incidence of RBC transfusions between the 2 groups.    
Secondary Objective(s)  
To summariz e the following for each dosing strategy:  
â€¢ Transfusion burden  
â€¢ Time to first RBC transfusion 
â€¢ Achieved Hb concen tration  
â€¢ Cumulative dose of darbepoetin alfa 
To describe the difference in each of the above between the two dosing strategies.  
Safety Objective:  To describe the safety profile of darbepoetin alfa, including adverse events 
and the occurrence of adjudicated clinical events of interest . 
Exploratory Objectiv e(s) 
To describe with each dosing strategy:  
â€¢ Dose and Hb- related parameters  
â€¢ Initial Hb response and resulting dose and achieved Hb 
â€¢ Duration of hospi[INVESTIGATOR_059]  
â€¢ Allosensitization over time  
Hypotheses:   The incidence of RBC transfusions in each treatment group (Hb- based titration 
group and fixed dose group) and their difference will be estimated, and no formal hypothesis will 
be tested.  The width of the 95% confidence interval (CI) of the transfusion incidence rate is 
expected to be < 10% (ie, Â± 5% around the point estimate) in each group and the width of the 
95% CI of the difference in transfusion incidence rates is expected to be < 14% (ie , Â± 7% around 
the point estimate).   The efficacy and safety  of each treatment group will  be described, as these 
aspects will assist in the determination of a preferred dosing regimen. 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 4 of 67 
 Primary Endpoint:  Receipt of 1 or more RBC transfusion  
Secondary Endpoint(s)   
â€¢ Total number of units of RBC transfused 
â€¢ Time to first RBC trans fusion  
â€¢ Average achieved Hb concentration while receiving investigational product  
â€¢ Cumulative dose of darbepoetin alfa 
Safety E ndpoint(s) 
â€¢ Time to major clinical events:  
âˆ’ Composite of all -cause mortality and the occurrence of major cardiovascular events 
(strok e, myocardial infarction, and decompensated heart failure)  
âˆ’ Composite of all -cause mortality, stroke or myocardial infarction, ie,  major adverse 
cardiovascular events (MACE)  
âˆ’ All-cause mortality  
âˆ’ Cardiovascular mortality  
âˆ’ Stroke  
âˆ’ Myocardial infarction  
âˆ’ Decompens ated heart failure 
âˆ’ Thromboembolic events  
âˆ’ Vascular access thrombosis  
â€¢ Adverse events  
â€¢ Blood pressure and pulse  
â€¢ Anti-erythropoietic protein antibodies  
Exploratory Endpoint(s) 
â€¢ Darbepoetin alfa dose received at each study visit  
â€¢ Hb concentration at each study vis it 
â€¢ Hb concentration change from baseline at each study visit  
â€¢ Time to first Hb concentration â‰¥ 10.0 g/dL  
â€¢ Proportion of Hb measurements â‰¥ 10.0 g/dL  
â€¢ Hb rate of change in a 4 week interval at each study visit  
â€¢ Hb variability, defined as the intrasubject standard deviation over a 6 month rolling window  
â€¢ Initial Hb response, defined as the change of Hb concentration from baseline at week 5 
â€¢ Darbepoetin alfa dose over time by [CONTACT_835737]  
â€¢ Hb over time by [CONTACT_835737]  
â€¢ Number of days hospi[INVESTIGATOR_057] 
â€¢ Anti-human leukocyte antigen (HLA)  antibodies  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 5 of 67 
 Study Design:  This is a phase 3, multicenter, randomized, double- blind, parallel group study.  
Anemic, ND -CKD subjects, without recent ESA use,  will be randomized to 1 of 2 dosing 
strategies .  In the Hb- based titration group, darbepoetin alfa doses will be titrated to maintain 
Hb â‰¥ 10.0 g/dL.  In the other group, subjects will receive a fixed dose of darbepoetin alfa.  All 
subjects will receive investigational product (IP) as a subcutaneous injection every 4 weeks 
(Q4W).  Treatment group, darbepoetin alfa doses, and protocol specified Hb concentrations will 
be blinded to the investigator, subjects and study team.  Subjects will be followed for 
approximately 2 years from the date of randomization.  
Sample Size:   A total of approximately 750 subjects (approximately 375 per treatment group)  will 
be randomized. 
Summary of Subject Eligibility Criteria    
Anemic ND-CKD  subjects:  
â€¢ Age 18 or older  
â€¢ Two Hb concentrations < 10.0 g/dL at least 2 week s apart   
â€¢ Not currently receiving dialysis with an e stimated  glomerular filtration rate of 
< 45.0 mL/min/1.73m2 during screening  
â€¢ Iron replete, defined as a transferrin saturation (TSAT) â‰¥ 20% and a ferr itin â‰¥ 100 ng/mL  
â€¢ Clinically stable by [CONTACT_835738]:  
â€¢ Received erythropoiesis stimulating agents ( ESAs) within 4 weeks of screening  
â€¢ Received  an RBC transfusion within 8 weeks of screening  
â€¢ Received intravenous  iron or had changes to oral iron therapy within [ADDRESS_1160263] (darbepoetin alfa or placebo) will be administered subcutaneously every 
4 weeks.  Darbepoetin alfa will be supplied as a clear, colorless, sterile protein solution in singl e 
use prefilled syringes (PFS) at concentrations of 10, 20, 30, 40, 50, 60, 80, 100, 150, 200 and 
300 Âµg.  Placebo will be provided in similar PFS as a clear , colorless , sterile  solution.  
The protocol specified doses (PSD) for use in this study are 10, 20,  30, 40, 50, 60, 80, 100, 120, 
150, 200, 250, and 300 Âµg.   
Every 4 weeks a protocol specified Hb will be measured using a n modified  Hb point of care 
(POC)  devic e and the results will be blinded.  The codes  provided by [CONTACT_835739] (SBP) will be entered into the interactive voice 
response/interactive web response ( IVR/IWR ) system at each dosing visit. The mean SBP 
obtained from additional blood pressure monitoring visits will also be entered into the IVR/IW R 
system.  
In both dosing groups, the dose of investigational product will be withheld if the subjectâ€™s mean 
SBP is â‰¥ 160 mmHg for three consecutive visits  (including blood pressure monitoring visits) .  
Investigational product will be restarted at the dosing visit when the mean SBP is â‰¤ 140 mmHg.  
Subjects randomized to the Hb- based titration group will receive an initial dose of 
darbepoetin alfa of 0.45 Âµg/kg, based on the subjectâ€™s screening weight, rounded down to the 
next lower PFS strength.  Subsequently, the dose of darbepoetin alfa will be titrated based on the Hb concentration at the current visit and rate of rise (ROR) as outlined in the table below.  The Hb 
ROR will be determined by [CONTACT_835740].  An IVR/IWR system will be used to determine and assign each dose.  
Subjects may be assign ed [ADDRESS_1160264]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 6 of 67 
 Dosing Algorithm for Hb -based Titration Group  
Hb (g/dL)  Hb ROR (g/dL/4W)  
â‰¤ 1.0  > 1.0 and â‰¤ 2.0 > 2.0  
<10.0  â†‘ to next higher PSDa  Maintain  â†“ to next lower PSDb 
10.0-10.5 Maintai n â†“ to next lower PSDb â†“ to next lower PSDb 
>10.5 -11.0 â†“ to next lower PSDb â†“ to next lower PSDb Placeboc 
>11.0  Placeboc Placeboc Placeboc 
a Subjects receiving 300 Âµg who require a dose increase will continue to receive 300 Âµg 
b Subjects receiving 10 Âµg who require a dose reduction will receive placebo  
c Restart darbepoetin alfa when Hb < 10.0 g/dL, at next lower PSD  
Subjects randomized to the fixed dose group will receive a fixed dose of darbepoetin alfa 
throughout the study of 0.45 Âµg/kg, based on the subjectâ€™s screening weight, rounded down to the 
next lower PFS strength.  The same dose of darbepoetin alfa will then be administered Q4W for 
the duration of the study, with 1 exception: if the Hb is > 12.0 g/dL, the darbepoetin alfa dose will 
be withheld and placebo will be administered until the Hb falls below 10.0 g/dL, at which time the darbepoetin alfa dose will be restarted.   In order to maintain the blind when a subject in the 
Hb-based titration group is assigned [ADDRESS_1160265] .  
Throughout the study, investigators should provide adequate supportive care.  It is recommended 
that iron be administered to ensure TSAT l evels of â‰¥ 20% and serum ferritin â‰¥ 100 ng/mL and 
blood pressure be monitored and managed as appropriate, such as to target a SBP <  130 mmHg 
and a diastolic blood pressure ( DBP) < [ADDRESS_1160266] visits and assessments will occur from the time of screening through the end of study.  At the 
conclusion of  the scre ening period, eligible subjects will be randomized in a 1:1 ratio to 1 of 
2 dosing strategies:  
â€¢ Hb-based titration group:  Darbepoetin alfa titrated to maintain Hb â‰¥ 10.0 g/dL  
â€¢ Fixed dose group:  Weight -based dose of darbepoetin alfa that will not be titrated  
Randomization will be stratified by [CONTACT_835741] 12 months prior to random ization (yes/no) and site practice setting (nephrology/non- nephrology).  
Assessment s during the study visits may include:  
â€¢ Recording of transfusions, adverse events, concomitant medications, hospi[INVESTIGATOR_835726] 
â€¢ Physical assessments (eg, blood pressure)  
â€¢ Collection of laboratory samples for evaluation of blood chemistry, hematology and iron 
status  
â€¢ Collection of blood samples for biomarker s 
Subject s ending investigational product prior to week [ADDRESS_1160267] be followed for the collection of RBC transfusions and endpoint data for adjudication.  
 
RBC 
transfusions should be performed as deemed necessary by [CONTACT_835742].  Information regarding the context surrounding RBC transfusions will be collected throughout the study including units of RBCs transfused, the 
transfusion setting (eg, dialysis center, intensive care unit, emergency department)  and clinical 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 7 of 67 
 events (eg, bleeding, surgery).  This information will be reviewed by [CONTACT_835743] (CEC).  
Events of death,  myocardial infarction, stroke, decompensated heart failure and 
thromboembolism, including vascular access thrombosis,  will also be collected from 
randomization through the end of the study and adjudi cated in a blinded fashion by [CONTACT_835744] .  
Adverse events (AEs) will be collected from the time of randomization through [ADDRESS_1160268].  Serious adverse events will be collected from the date of consent.  Any serious adverse events with a fatal outcome (regardless of possible relationship to investigational product) occurring through the end of the subjectâ€™s participation on the study are to be reported to [COMPANY_010].    
For a full list of study procedures, including the timing of each procedure, please refer to Section [ADDRESS_1160269] plus 3 months  or end of study, 
whichever is earlier  (on-treatment approach).  
For the primary endpoint, the proportion of subjects in each treatment group receiving at least 1 RBC transfusion during the evaluation period will be presented with 2-sided 95% CIs .  The 
difference in proportions between treatment groups and the relative risk ratio will be described 
with 2-sided 95% CIs .  Confidence intervals will be derived using normal approximation.  The 
primary analysis will be repeated by [CONTACT_205995] . 
As a sensitivity analysis , the primary analysis will be repeated using all randomized subjects with 
the evaluation period beginning at the date of randomization and subjects will be censored at the 
end of study (on- study approach).  
Sensitivity analyses will also be performed to assess the impact of potential differential follow -up 
on the primary endpoint .  Exposure- adjusted subject incidence of receiving at least 1 RBC 
transfusion will be calculated with 95% CI using Chi -square approximation to the Poisson 
distribution for both on- treatment and on -study approaches.  
For the analyses of the secondary endpoints: total number of units of RBC transfused per subject will be summarized for each treatment group.  Time to first RBC transfusion using both 
on-treatment and on- study approaches will be described for each treatment  group.  Average 
achieved Hb concentration while receiving investigational product will be analyz ed as average Hb 
using the area under th e curve (AUC) method.  Cumulative doses of darbepoetin alfa adjusted for 
investigational  product exposure time will also be described. 
Safety endpoints  will include the descriptive summary of the time to adjudicated event endpoint  
by [CONTACT_1570], using Kaplan -Meier curves, Kaplan- Meier percentiles, the number of subjects 
censored, and the number of subjects with events.   Subject incidence of adverse events will be 
tabulated by [CONTACT_9313], high level group term, and preferred term by [CONTACT_1570].  Adverse events of interest will be tabulated by [CONTACT_1570].  Subgroup analyses will be 
presented for all adverse events.  
An independent Data Monitoring Committee (DMC) will review unblinded study data on a regular basis throughout the duration of the study .  The DMC may recommend modifying or stoppi[INVESTIGATOR_90348], or suspending enrollment.  This recommendation can be based on any safety concerns, lack of efficacy/futility, or preponderance of early evidence of efficacy.  The DMC will conduct an interim analysis , which will occur when approximately 33% of subjects  have completed 12 months 
of planned study follow -up.   
For a full description of statistical analysis methods, please refer to Section  10. 
Spons or:  [COMPANY_010] Inc.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 8 of 67 
 Study Design and Treatment Schema  
Written Informed Consent  
Hb-Based Titration  
â€¢ N = 375  
â€¢ Initiate at 0.45 Âµg/kg darbepoetin alfa Q4W  
â€¢ Titrate to maintain Hb â‰¥ 10.0 g/dL  Fixed  Dose  
â€¢ N = 375  
â€¢ 0.45 Âµg/kg darbepoetin alfa Q4W  
â€¢ No titration  
 Screening Period  
2-4 weeks  
 
Eligible subjects 
randomized in 1:1 ratio 
(N=750)  
Treatment P eriod  
Approximately [ADDRESS_1160270]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 9 of 67 
 Study Glossary  
Abbreviation or Term  Definition/Explanation  
AE Adverse Event  
AUC  Area Under the Curve  
CBC  Complete Blood Count  
CEC  Clinical Endpoint Committee 
CHOIR  Correction of Hemoglobin and Outcomes in Renal Insufficiency 
CI Confidence Interval  
CKD  Chronic Kidney Disease   
CRP  C-Reactive Protein  
CV Cardiovascular  
DBP Diastolic Blood Pressure  
DMC  Data Monitoring Committee 
ECG  Electrocardiogram  
eCRF  electronic Case Report Form 
eGFR  estimated Glomerular Filtration Rate  
Electronic Source Data 
(eSource)  Source data captured initially into a permanent electronic record used for the reconstruction and evaluation of a trial.  
Electronic Trial Operations (ETO) System  An electronic system that is used to facilitate the operations of a clinical trial through the collection of study related data.   Most 
common applications of an ETO system within a clinical trial are: subject randomization and product management.   Term 
synonymous with the industry term IVR or IVRS.  Note: An 
individual can interface with an ETO system by [CONTACT_835745].  See definitions of IVR and IWR below.  
End of Study for individual subject (EOS)  Defined as the last day that protocol specified procedures are conducted for an individual subject  
End of Study  
(primary completion)  Defined as the date when the last subject is assessed or receives an intervention for the purposes of final collection of data for the primary endpoint  
Enrollment  Defined as the date the subject is randomly assigned to a 
treatment group or "randomized"  
EPO  Erythropoietin  
ESA Erythropoiesis Stimulating Agent  
ET Early Termination  
GCP  Good Clinical Practice  
GI Gastrointestinal  
Hb Hemoglobin  
HBV Hepatitis B Virus  
Page [ADDRESS_1160271]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 10 of 67 
 Abbreviation or Term  Definition/Explanation  
HCT Hematocrit  
HCV  Hepatitis C Virus  
HemoCue Modified  hemoglobin point of care device  
HIV Human Immunodeficiency Virus  
HLA Human Leukocyte Antigen  
HTLV  Human T -Lymphotropic Virus  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
Interactive Voice Response 
(IVR)  Telecommunication technology that is linked to a central computer in real time as an interface to collect and process information.  
Interactive Web Response 
(IWR)  Web based technology that is linked to a central computer in real time as an interface to collect and process information.  
IP Investigational Product  
IRB Institutional Review Board 
IV Intravenous  
KDOQI  The National Kidney Foundation Kidney Disease Outcomes Quality Initiative  
MACE  Major Adverse Cardiovascular Events  
MCH  Mean Corpuscular Hemoglobin  
MCHC  Mean Corpuscular Hemoglobin Concentration  
MCV  Mean Corpuscular Volume 
MedDRA  Medical Dictionary for Regulatory Activities  
MI Myocar dial Infarction  
MPV  Mean Platelet Volume  
ND-CKD  Chronic Kidney Disease Not on Dialysis  
PFS Prefilled Syringe  
PIN Personal Identification Number  
POC  Point of Care  
PSD Protocol Specified Dose  
PTCA Percutaneous Transluminal Coronary Angioplasty  
Q4W  Every 4 Weeks  
Randomization  Defined as the date the IVR/IWR system is contact[CONTACT_835746] a subject to a treatment group.  Randomization occurs only after the subject has successfully met all screening eligibility criteria.  
Page [ADDRESS_1160272]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 11 of 67 
 Abbreviation or Term  Definition/Explanation  
RBC  Red Blood Cell  
RDW  Red Cell Distribution Width  
rHuEPO  recombinant Human Erythropoietin  
ROR Rate of Rise  
SAE Serious Adverse Event  
SBP Systolic Blood Pressure  
SC Subcutaneous  
SD Standard Deviation  
SE Standard Error  
Source Dat a Information from an original record or certified a copy of the 
original record containing patient information for use in clinical research.   The information may include, but is not limited to, 
clinical findings, observations, or other activities in a cli nical 
trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source documents (original records or certified copi[INVESTIGATOR_014]). (ICH Guideline (E6)).  Examples of source data include Subject ID, Randomization ID, and Strati fication Value.  
Study week  7 calendar days  
TACO  Transfusion Associated  Cardiac Overload  
Target visit date  The calculated date for study visits based on the date of randomization  
TIA Transient Ischemic Attack  
TIBC  Total Iron Binding Capacity  
TRALI  Transfusion- Related Acute Lung Injury  
TREAT  Trial to Reduce Cardiovascular Events with AranespÂ® Therapy  
TSAT  Transferrin Saturation  
WBC  White Blood Cell  
Page [ADDRESS_1160273]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160274] ENROLLMENT  .................................................................................... 24 
5.1 Screening .................................................................................................. 24 
5.2 Randomization  .......................................................................................... 25 
5.3 Site Personnel Access to Individual Treatment Assignments  .................... 25 
6. TREATMENT PROCEDURES  .............................................................................. 26 
6.1 Classification of Products and Medical Devices ......................................... 26 
6.2 Darbepoetin alfa  ........................................................................................ 26
 
6.3 Placebo ..................................................................................................... 26 
6.4 Dosage, Administration, and Schedule ...................................................... 26 
6.4.1  Dosage Adjustments  ................................................................. 27 
[IP_ADDRESS]  Dosage Adjustments Based on Systolic 
Blood Pressure Values  ............................................ [ADDRESS_1160275]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 13 of 67 
 [IP_ADDRESS]  Dosage Adjustments Based on Hb 
Parameters  ............................................................. 28 
[IP_ADDRESS]  Missed Doses .......................................................... 28 
6.5 Concomitant Therapy  ................................................................................ 29 
6.6 Medical Devices  ........................................................................................  29 
6.6.1  Modified HemoCue Hb 201+ System Hemoglobin 
Analyzer  .................................................................................... [ADDRESS_1160276] Complaints  ................................................................................... 30 
6.8 Excluded Treatments During Study Period  ................................................ 30 
7. STUDY PROCEDURES  ....................................................................................... 30 
7.1 General Study Procedures  ........................................................................ 30 
7.1.1  Screening Evaluations  ...............................................................  31 
7.1.2  Rescreening Evaluations  ........................................................... 32 
7.1.3  Study Day 1 Evaluations  ........................................................... 32 
7.1.4  Treatment Period Evaluations  ................................................... 33 
[IP_ADDRESS]  Routine Study Visits  ................................................ 33 
[IP_ADDRESS]  Additional Visits for Blood Pressure 
Monitoring ...............................................................  [ADDRESS_1160277]  ....................... 34 
7.1.6  Early Termination  ...................................................................... 34 
7.1.7  End of Study Evaluations  .......................................................... 34 
7.2 Description of General Study Procedures  ................................................. 35 
7.2.1  Informed Consent  ...................................................................... 35 
7.2.2  Medical and Surgical History  ..................................................... 35 
7.2.3  Physical Examination ................................................................ 35 
7.2.4  Blood Pressure and Pulse ......................................................... 35 
7.2.5  Hemoglobin  ............................................................................... 36 
7.2.6  RBC Transfusions  ..................................................................... 36 
7.2.7  Hospi[INVESTIGATOR_835727]  ................... 36 
7.2.8  Adverse Events  ......................................................................... 37 
7.2.9  Concomitant Medications  .......................................................... 37 
7.2.10  Electrocardiogra m (ECG)  .......................................................... [ADDRESS_1160278]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160279] Treatment Assignments by [CONTACT_21912]  ............................................................................................. 48 
10.4  Interim Analysis and Early Stoppi[INVESTIGATOR_130]  ........................................ 48 
10.5  Planned Methods of Analysis  .................................................................... 49 
10.5.1  General Approach/Considerations  ............................................. 49 
10.5.2  Analysis of Key Study Endpoints  ............................................... 49 
[IP_ADDRESS]  Efficacy Endpoints  ................................................... 49 
[IP_ADDRESS]  Secondary Endpoints  .............................................. 50 
[IP_ADDRESS]  Safety Endpoints  ..................................................... 50 
[IP_ADDRESS]  Exploratory Endpoints  ............................................. 51 
10.5.3  Additional Analyses  ................................................................... 51 
11. REGULATORY OBLIGATIONS  ............................................................................ 52 
11.1  Informed Consent  ...................................................................................... 52 
11.2  Independent Ethics Committee/Institutional Review Board ........................ [ADDRESS_1160280]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160281] of Appendices 
Appendix  A.  Schedule of Assessments  ........................................................................ 61 
Appendix  B.  Additional Safety Assessment Information  ................................................ 62 
Appendix  C.  Sample of the Serious Adverse Event Worksheet/electronic 
Serious Adverse Event (eSAE) Contingency Report Form...................... [ADDRESS_1160282]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 16 of 67 
 1. OBJECTIVES  
1.1 Primary  
To evaluate the incidence of red blood cell (RBC) t ransfusions in chronic kidney disease 
subjects not on dialysis  (ND- CKD)  using either a hemoglobin (Hb) -based titration 
algorithm or a weight -based dose that will not be titrated (fixed dose), and to evaluate 
the difference in the incidence of RBC transfusions between the 2 groups .   
1.2 Secondary  
To summarize the following for each dosing strategy:  
â€¢ Transfusion burden  
â€¢ Time to first RBC transfusion  
â€¢ Achieved Hb concentration  
â€¢ Cumulative dose of darbepoetin alfa  
To describe the difference in each of the above between the two dosing strategies.  
1.[ADDRESS_1160283] . 
1.4 Exploratory  
To describe with each dosing strategy : 
â€¢ Dose and Hb-related paramet ers  
â€¢ Initial Hb response and resulting dose and achieved Hb 
â€¢ Duration of hospi[INVESTIGATOR_059] 
â€¢ Allosensitization over time 
2. BACKGROUND AND RATIONALE  
2.1 Disease  
Anemia is a common and debilitating complication of chronic kidney disease ( CKD) .  
It results primarily fr om decreased production of erythropoietin by [CONTACT_10521] 
(Eschbach and Adamson, 1985 ) and becomes increasingly prevalent and severe as 
kidney function declines ( Moranne et al, 2009 ; Astor et al, 2002; Kazmi et al, 2001).  
This renal anemia itself may be severe enough to require RBC transfusions or may 
contribute to the need for a RBC transfusion in patients who experience a clinical event which worsens the anemia (eg , bleeding, infection, or inflammation).   
Avoidance of RBC transfusions is desirable due to the association of transfusions with a number of risks as well as because of blood inventory constraints 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 17 of 67 
 (Goodnough  and Shander, 2007).  Some risks, including transfusion- related acute lung 
injury (TRALI), transfusion associated cardiac overload (TACO), hemolytic reactions, 
and bacterial sepsis, have been associated with transfusion- related death 
(Leo and Pedal, 2010 ; Eder  and Chambers, 2007 ).  Transmission of blood- borne viral 
pathogens such as human immunodeficiency virus (HIV), human T- lymphotropic virus  
(HTLV), hepatitis B (HBV) or hepatitis C (HCV) is a lesser risk of RBC transfusions due 
to contemporary screening practices, but the risk has not been completely eliminated.  
Concerns remain regarding transmission of pathogens such as West Nile virus  for which 
blood products are not routinely screened ( Busch et al, 2003) .  The possibility for RBC 
transfusions to transmit Creutzfeldt -Jakob disease is also a concern ( Busch et al, 2003).  
Chronic transfusions can also lead to iron overload and its complications (Despotis  et al, 2007 ; Goldman and Vanherweghem, 1987).   
CKD patients are at higher risk for specific complications of transfusions.  These include volume overload and hyperkalemia ( Despotis et al, 2007; Simon and Bove, 1971 ).  
In addition, transfusions may lead to allosensitization ( Murphey and Forsthuber, 2008).  
Allosensitization can increase the time a patient spends on the kidney transplant wait -list 
or even preclude transplant eligibility ( Susal et al, 2009), and has also been associated 
with shorter graft survival ( Seetharam et al, 2010; Opelz, 2005)  and accelerated 
atherosclerosis ( Hill et al, 2011 ). 
2.2 Darbepoetin alfa Background  
Erythropoie sis stimulating agents (ESAs) bind to the erythropoietin receptor and 
stimulate erythropoiesis by [CONTACT_835747] (EPO) .  
They have been shown to effectively elevate and maintain Hb concentrations in patients 
with renal anemia and reduce transfusion requirements. 
Darbepoetin alfa is an ESA produced in Chinese hamster ovary cells as a secreted 
glycoprotein by [CONTACT_12060].  It is a 165 amino acid protein that 
contains 5 N -linked  oligosaccharide chains, rather than the 3 contained in human EPO .  
The additional carbohydrate chains  increase  the molecular weight and carbohydrate 
content of the glycoprotein, which gives darbepoetin alfa an approximately 3- fold longer 
serum half -life and mean residence time than recombinant human erythropoietin 
(rHuEPO) in animal models and subjects with CKD, allowing extended administration 
dosing intervals ( Macdougall, 2000 ; Egrie et al, 1993).  Details of the chemistry, 
preclinical pharmacology, pharmacokinetics, toxicology, and clinical experience with darbepoetin alfa are contained in the Investigatorâ€™s Brochure.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160284] been in wide use in CKD patients both on dialysis and 
not on dialysis to raise Hb concentrations  and reduce the need for RBC transfusions.  
Because observational studies had shown an association between anemia and 
increased cardiovascular ( CV) morbidity and mortality in ND-CKD patients 
(Collins,  2003; McClellan et al, 2002 ; Sarnak et al, 2002; Al Ahmad et al, 2001; 
Mann,  1999 ; Levin et al, 1999), clinical trials were conducted in this population to 
evaluate potential CV benefits of ESAs.  Contrary to the hypothesis, 2 large clinical trials did not demonstrate a CV benefit when anemia was treated.  The Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study evaluated outcomes in 
subjects with moderate anemia treated with epoetin alfa to Hb concentrations of 13.5 g/dL vs 11.3 g/dL ( Singh et al, 2006).  The CHOIR study identified an increased risk 
for death and serious CV events in the higher Hb target arm (hazard ratio 1.34; 
95% confidence interval [CI] 1.03 to 1.74), the imbalance being mostly for death and 
hospi[INVESTIGATOR_19934].  The Trial to Reduce Cardiovascular Events with 
Aranesp
Â® Therapy (TREAT) evaluated ND -CKD subjects with moderate anemia and 
type 2 diabetes who were randomized to receive either treatment with darbepoetin alfa 
to a target Hb concentration of 13 g/dL or placebo with rescue darbepoetin alfa therapy if 
Hb concentration fell < 9 g/dL ( Pfeffer et al, 2009).  The TREAT study did not 
demonstrate a benefit on the primary composite CV endpoint of all cause mortality or CV 
event (hazard ratio 1.05; 95% CI 0.94 to 1.17), however, an increased risk of stroke was observed when compared to the placebo group (hazard ratio 1.92; 95% CI 1.38 to 2.68).  The mechanism for the increased risk observed when targeting high Hb concentrations has not been determined.  It has been suggested that exposure to high doses, high 
cumulative dose of ESA, Hb excursions, and rapid Hb rises might contribute to these 
risks.  Thus, there is a desire to define a dosing regimen that can retain the transfusion benefits of ESA treatment while minimizing potential contributing factors listed above.  
Although in CKD patients ESAs have historically been titrated to achieve a predefined Hb concentration, this may not be the only possible dosing strategy.  In particular, a 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 19 of 67 
 dosing strategy using a fixed dose could mitigate some of the potential contributing 
factors of increased risk while effectively avoiding RBC transfusions.  A fixed dose 
strategy will avoid exposure to high doses entirely and could decrease the cumulative 
dose exposure.  Additionally, by [CONTACT_835748], the occurrence of Hb excursions and rapid Hb rises may be minimized.  A fixed dose may also reduce Hb cycling, which 
may be associated with frequent dose changes, which has been associated with worse 
outcomes in some observational studies of dialysis patients ( Gilbertson et al, 2008; 
Weinhandl et al, 2011 ).  A consistent, fixed dosing strategy, without titration, may also 
simplify therapy for patients and providers, which may potentially improve compliance 
and minimize dosing errors. 
The ability of treatment with a fixed dose to effectively reduce the need for transfusions 
is unknown.  One prospective single arm study designed to use primarily 1 fixed dose of 
epoetin alfa has suggested that such a strategy can reduce RBC transfusions in anemic 
ND-CKD patients ( Provenzano et al, 2004).  During the short 16- week study, 3.7% of 
patients were transfused compared to 11.1% of patients within 6 months prior to 
enrollment.  However, this study enabled the â€œfixed doseâ€ to be increased or decreased, and less than half the patients were maintained on the original 10,[ADDRESS_1160285] 
incidenc e of RBC transfusions (administered as deemed clinically necessary) in each 
group and the difference in incidence of RBC transfusions between the 2 groups .  
However, determining a preferred dosing regimen will also be based on multiple 
considerations, such  as cumulative darbepoetin alfa dose, total number of units of 
transfusions , Hb concentration, Hb- related parameters (eg, Hb variability, excursions, 
rate of change), and  adverse (eg, CV) events .  Given these considerations, an 
estimation approach was chos en for this study . 
The dosing algorithm that will be used in the Hb- based titration group is intended to 
maintain Hb concentration â‰¥ 10.0 g/dL , with a starting dose of 0.45 Âµg/kg, to be 
administered every 4 weeks ( Q4W ).  Model -based simulations were used to select a 
fixed dose that would achieve approximately the same population mean 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 20 of 67 
 Hb concentration at the end of the s tudy.  The  simulations , conducted in a similar 
fashion as previously published ( Doshi et al, 2010), predicted  that a darbepoetin alfa 
dose of 0.45  Âµg/kg/Q4W should be used .  
The starting dose is the same for both of the dosing algorithms .  Thus it will be possible 
to analyze the dose received and achieved Hb concentrations  by [CONTACT_835749] . 
2.4 Clinical Hypotheses 
The incidence of RBC transfusions in each treatment group (Hb -based titration group 
and fixed dose group) and their difference will be estimated, and no  formal hypothesis  
will be tested .  The width of the 95% CI of the tran sfusion incidence rate is expected to  
be < 10% (ie, Â± 5% around the point estimate) in each group and the width of the 
95% CI of the difference in transfusion incidence rates is expected to be 
< 14% (ie, Â± 7% around the point estimate).  The efficacy and safety of each treatment 
group will be described, as these aspects will assist in the determination of a preferred 
dosing regimen.  
3. EXPERIMENTAL PLAN  
3.1 Study Design 
This is a phase 3, multicenter, randomized, double- blind, parallel group study.  Anemic, 
ND-CKD subjects , without recent ESA use,  will be randomized to 1 of 2 dosing 
strategies.  In the Hb -based titration group, darbepoetin alfa doses will be titrated to 
maintain Hb â‰¥ 10.0 g/dL.  In the other group, subjects will receive a fixed  dose of 
darbepoetin alfa.  All subjects will receive investigational product  (IP) as a subcutaneous 
injection Q4W.  Treatment group, darbepoetin alfa doses, and protocol specified Hb 
concentrations will be blinded to the investigator, subjects and study team.   The overall 
study design is described by a study schema  at the end of the protocol synopsis section.  
The study endpoints are defined in Section 10.1. 
3.2 Number of Centers  
The study will be conducted in approximately 350 sites in North America.   Sites that do 
not enroll subjects within 6 months  of site initiation may be closed.   
3.3 Number of Subjects  
Participants in this clinical investigation shall be referred to as â€œsubjectsâ€.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160286] is approximately 2 years, which 
includes the following:  
â€¢ 2- to 4-week screening period 
â€¢ 100-week on -study period including 
âˆ’ 96-week trea tment period 
âˆ’ 4-week follow -up period, after final dose of investigational product for collection 
of RBC transfusions and safety information (eg, adverse events ) 
3.4.[ADDRESS_1160287] ELIGIBILITY  
Investigators will be expected to maintain a screening log of all potential study 
candidates that includes limited information about the potential candidate (eg, sex, age, 
race), date and outcome of the screening process (eg, enrolled into the study, reason for ineligibility, or refused to participate) .  This log may be completed and updated via an 
Electronic Trial Operations (ETO) System (eg, interactive voice response system ).  
Before any study  specific  procedure, the appropriate written informed consent must be 
obtained (see Section 11.1).  For purposes of eligibility, screening is defined as the first 
screening procedure following signing of the informed consent . 
4.[ADDRESS_1160288] 1 historic 
estimated glomerular filtration rate ( eGFR ) < 45.0 mL/min/1.73m
[ADDRESS_1160289] 
12 weeks  prior to screening 
4.1.3  Not currently receiving dialysis with an eGFR < 45 .0 mL/min/1.73m2, per 
the central laboratory during screening 
4.1.4  Chronic anemia due to renal fail ure  
4.1.5  Two Hb concentrations < 10.0 g/dL, at least 2 weeks apart during screening 
using t he modified Hb point of care (POC) device  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 22 of 67 
 4.1.6  Iron replete, defined as a transferrin saturation (TSAT ) â‰¥ 20% and a ferritin 
â‰¥ 100 ng/mL, per the central laboratory during screening 
4.1.7  Vitamin B12 and folate replete, defined as a vitamin B12 level > 180 pg/mL 
and a folate concentration > 7 nmol/L, per the central laboratory during 
screening 
4.1.[ADDRESS_1160290] has provided written informed consent  
4.2 Exclusion Criteria  
General  
4.2.1  Systemic hematologic disease (eg, sickle cell anem ia, myelodysplastic 
syndrome, hematologic malignancy)  
4.2.2  Current or prior malignancy within 5 years of screening, with the excepti on of 
non-melanoma skin cancers  and cervical intraepi[INVESTIGATOR_28601]  
4.2.3  Treatment for any malignancy (eg, radiation, chemotherapy , hormone 
therapy, or biologics) within [ADDRESS_1160291] feeding, or might become pregnant during the 
study or within 4 weeks  after the end of treatment  
4.2.6  Currently receiving intravenous antibiotics for treatment of an active infection 
4.2.7  Known HIV positive  
4.2.8  Currently receiving systemic immunosuppressive therapy  with the exception 
of prednis (ol)one â‰¤ 10 mg per day (or the steroid equivalent)  
4.2.9  History of any organ transplant   
4.2.10  Currently enrolled in another interventional study (eg, studies which req uire 
medical device use or drug therapy or with protocol required procedures ), or 
less than 4 weeks  since ending another interventional study(s) or receiving 
investigational agent(s)  
4.2.[ADDRESS_1160292] and investigatorâ€™s knowledge  
4.2.[ADDRESS_1160293] to give written informed consent and/or comply with all required study procedures  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 23 of 67 
 Within 24 weeks of screening  
4.2.16  Occurrence of any of the following:  
â€¢ Stroke 
â€¢ Myocardial Infarction (MI)  
Within 8 weeks of screening  
4.2.17  Receipt of any of the following: 
â€¢ RBC transfusion  
4.2.18  Occurrence of any of the following:  
â€¢ Seizure  
â€¢ Clinically relevant active bleeding (eg, gastrointestinal [GI] bleed)  
â€¢ Any hospi[INVESTIGATOR_835728] 4 weeks of screening  
4.2.19  R eceipt of any intravenous  (IV) iron therapy  
4.2.20  Changes in oral iron therapy  
4.2.21  Receipt of ESA therapy  
During screening  
4.2.22  Diagnosis or  treatment of malignancy, with the exception of non -melanoma 
skin cancers  and cervical intraepi[INVESTIGATOR_28601]  
4.2.23  Receipt of any of  the following:  
â€¢ ESA therapy  
â€¢ RBC transfusions  
â€¢ IV iron therapy  
4.2.24  Changes in oral iron therapy  
4.2.25  Occurrence of any of the following:  
â€¢ Stroke  
â€¢ MI  
â€¢ Seizure  
â€¢ Clinically relevant active bleeding (eg, GI bleed)  
â€¢ Any hospi[INVESTIGATOR_059] 
â€¢ Any o utpatient  surgery  

 3URGXFW'DUEHSRHWLQDOID
3URWRFRO1XPEHU
'DWH'HFHPEHU 3DJHRI
 8QFRQWUROOHGK\SHUWHQVLRQGHILQHGLQWKLVVWXG\DV
x DPHDQV\VWROLFEORRGSUHVVXUH6%3!PP+JDWERWK VFUHHQLQJ
YLVLWVRU
x DPHDQ6%3Â•PP+JDWDQ\ VFUHHQLQJYLVLWRU
x DPHDQGLDVWROLFEORRGSUHVVXUH'%3Â•PP+JDWDQ\ VFUHHQLQJYLVLW
([SHFWHGRUVFKHGXOHG 
 &KDQJHLQRUDOLURQWKHUDS\RUUHFHLSWRI,9LURQWKHUDS \ZLWKLQZHHNVDIWHU
UDQGRPL]DWLRQ
 5HFHLSWRID5%&WUDQVIXVLRQZLWKLQZHHNVDIWHUUDQGRP L]DWLRQ
 $Q\RUJDQWUDQVSODQWZLWKLQZHHNVDIWHUUDQGRPL]DWLRQ 
 ,QLWLDWLRQRIGLDO\VLVZLWKLQZHHNVDIWHUUDQGRPL]DWL RQ
 68%-(&7(152//0(17
%HIRUHVXEMHFWVPD\EHHQWHUHGLQWRWKHVWXG\$PJHQUHTXLUHVD FRS\RIWKHVLWHÂ¶V
ZULWWHQLQGHSHQGHQW HWKLFVFRPPLWWHHLQVWLWXWLRQDOUHYLHZERDUG,(&,5%DSSURYDO RIWKH
SURWRFROLQIRUPHGFRQVHQWIRUPDQGDOORWKHUVXEMHFWLQIRUPDW LRQDQGRUUHFUXLWPHQW
PDWHULDOLIDSSOLFDEOHVHH 6HFWLRQ $OOVXEMHFWVPXVWVLJQDQGSHUVRQDOO\GDWHWKH
FRQVHQWIRUPEHIRUHFRPPHQFHPHQWRIVWXG\VSHFLILFSURFHGXUHV 6XEMHFWVDUH
FRQVLGHUHGHQUROOHGZKHQWKH\KDYHEHHQUDQGRPL]HGWRWUHDWPHQW 
$OOVXEMHFWVZKRHQWHULQWRWKHVFUHHQLQJSHULRGIRUWKHVWXG\ ZLOOUHFHLYHDXQLTXH
VXEMHFWLGHQWLILFDWLRQQXPEHUEHIRUHDQ\VWXG\SURFHGXUHVDUHS HUIRUPHG7KH
LQYHVWLJDWRURUGHVLJQHHVKRXOGFRQWDFWWKH,QWHUDFWLYH9RLFH5 HVSRQVH,QWHUDFWLYH:HE
5HVSRQVH6\VWHP,95,:5WRUHJLVWHUVXEMHFWVWKDWVLJQWKHFR QVHQWIRUPDQGWR
REWDLQWKHXQLTXHVXEMHFWLGHQWLILFDWLRQQXPEHU7KLVQXPEHUZ LOOEHXVHGWRLGHQWLI\WKH
VXEMHFWWKURXJKRXWWKHVWXG\DQGPXVWEHXVHGRQDOOVWXG\GRFX PHQWDWLRQUHODWHGWR
WKDWVXEMHFW
7KHVXEMHFWLGHQWLILFDWLRQQXPEHUPXVWUHPDLQFRQVWDQWWKURXJKR XWWKHHQWLUHVWXG\LW
PXVWQRWEHFKDQJHGDWWKHWLPHRIUHVFUHHQLQJHQUROOPHQWRU UDQGRPL]DWLRQ 




 6FUHHQLQJ
7KHVFUHHQLQJSHULRGEHJLQVZKHQWKHVXEMHFWVLJQVDQGGDWHVWK HLQIRUPHGFRQVHQWDQG
FRQFOXGHVZKHQWKHVXEMHFWLVUDQGRPL]HGRUVFUHHQIDLOHG7KH VFUHHQLQJSHULRGLVDPP
D
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160294] the IVR/IWR system .   
If subjects are confirmed as eligible, the IVR/IWR system will continue to the  
randomization call and assign the investigational product.  Subjects must have their first 
dose of investigational product administered on this date.   At the completion of the call , a 
confirmation fax and/or e -mail will be sent to the site to verify that the correct information 
has been entered and to confirm the randomization.  
If subjects are not eligible for the study  due to: 
â€¢ the screening Hb concentration only, the IVR/IWR system will notify the investigator 
or designee that the subject is not eligible and record the date of the screen failure 
â€¢ reasons other than the screening Hb concentration, the investigator or designee will 
enter the date and reason for screen failure   
Subjects who fail screening may be rescreened as described in Section  7.1.[ADDRESS_1160295] screening procedure. 
5.2 Randomization 
Randomization by [CONTACT_21925]/IWR system will be done  in a 1:1 ratio to 1 of the 2 treatment 
groups (Hb- based titration group or fixed  dose group) based on the following 
stratification factors at the time of study entry:  
â€¢ Receipt of any RBC transfusion within the 12 months  prior to randomization (yes/no)  
â€¢ Site practice setting (nephrology/non- nephrology) , pre-specified by  [CONTACT_835750]  [INVESTIGATOR_835729] a schedule generated before the start of the study by [CONTACT_835751] .   
5.[ADDRESS_1160296] assigned will be maintained by 
[CONTACT_21925] /IWR system .  The investigator  will be provided with a unique personal 
identification number (PIN) to access the IVR /IWR system  in the event that they need to 
unblind the subject treatment  assignment.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160297]â€™s treatment assignment, but is required to do so within 
[ADDRESS_1160298]â€™s 
electronic case report form (eCRF) . 
6. TREATMENT PROCEDURES  
6.1 Classification of Products and Medical Devices 
The [COMPANY_010] Investigational Products used in this study include:   Darbepoetin alfa and 
placebo in a prefilled syringe (PFS) . 
The Investigational Product Instruction Manual (IPIM), a document external to this protocol, contains detailed information regarding the storage, prepa ration, and 
administration of darbepoetin alfa and placebo.  
The medical devices that are provided by [CONTACT_835752]:  A 
modified HemoCue Hb 201+ system hemoglobin analyzer  and an a uto inflate Blood 
Pressure Monitor. 
6.2 Darbepoetin alfa  
Darbepoetin alfa  will be manufactured and packaged by [CONTACT_21931] . and distributed 
using [COMPANY_010] clinical study drug distribution procedures.  Darbepoetin alfa will be 
presented as a clear, colorless, sterile protein solution in single use PFS in the following 
strengths:  10, 20, 30, 40, 50, 60, 80 , 100, 150, 200, and 300 Âµg.  
6.3 Placebo 
Placebo will be provided as a clear, colorless, sterile solution in PFS identical to those 
containing the active drug.  
6.4 Dosage, Administration, and Schedule  
Subjectsâ€™ Hb will be meas ured Q4W using an modified Hb POC  device provided by 
[CONTACT_11337].  The device will provide coded values that will be entered into IVR/IWR system at each scheduled dosing visit .  The IVR/IWR system will determine and assign the 
appropriate dose and individual box (es) of investigational product (darbepoetin alfa or 
placebo) for that specific visit  based on the Hb concentration and the dosing algorithms 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160299] will contain only 1 PFS that 
is to be administered at the study visit for which it has been assigned.   
The protocol specified doses (PSD) for use in this study are 10, 20, 30, 40, 50, 60, 80, 
100, 120, 150, 200, 250, and [ADDRESS_1160300] by [CONTACT_21925] /IWR system .  When this is required, the IVR/IWR 
will assign [ADDRESS_1160301] will be administered subcutaneously (SC) by [CONTACT_835753] Q4W  for the duration of the treatment period.  The starting 
dose of investigational product will be 0.45 Âµg/kg for both groups, using the subjectâ€™s 
body weight at screening Visit 1.  The dose obtained from this calculation will be 
rounded down to the next lower PFS strength.    
6.4.1  Dosage Adjustments  
All dose adjustments will be managed using the IVR/IWR  system .  In order to maintain 
the blind, subjects will receive a placebo injection in place of darbepoetin alfa  therapy 
when the dose of study drug is to be withheld per the dosing algorithm , for reasons other 
than elevated SBP.    
The maximum dose of darbepoetin alfa administered at any time during the study will be [ADDRESS_1160302] may be adjusted based on Hb parameters and SBP 
values.  
[IP_ADDRESS]  Dosage Adjustments Based on Systolic Blood Pressure Values  
If the subjectâ€™s mean SBP is â‰¥ 160 mmHg for two consecutive visits (including blood 
pressure 
 m
onitoring visits), the dose of investigational product will be withheld.   
If the subjectâ€™s dose is withheld for â‰¤ [ADDRESS_1160303]â€™s previous dose at the dosing visit when the mean SBP is â‰¤ [ADDRESS_1160304]â€™s dose is withheld for > [ADDRESS_1160305] will be restarted on the initial study dose at the dosing visit when the mean SBP is â‰¤ [ADDRESS_1160306]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 28 of 67 
 [IP_ADDRESS]  Dosage Adjustments Based on Hb Parameters  
[IP_ADDRESS].[ADDRESS_1160307] titrated based on the Hb concentration on the date of the visit, the 
corresponding Hb rate of rise (ROR), and the previously  assigned dose , as outlined in 
Table 1  below.   The Hb ROR will be determined by [CONTACT_835754] .  
Table 1 .  Dosing Algorithm for Hb-b ased Titration Group  
Hb (g/dL)  Hb ROR (g/dL/4W)  
â‰¤ 1.0  > 1.0 and â‰¤ 2.0 > 2.0  
<10.0  â†‘ to next higher PSDa  Maintain  â†“ to next lower PSDb 
10.0- 10.5 Maintain  â†“ to next lower PSDb â†“ to next lower PSDb 
>10.5 -11.0 â†“ to next lower PSDb â†“ to next lower PSDb Placeboc 
>11.0  Placeboc Placeboc Placeboc 
a Subje cts receiving 300 Âµg who require a dose increase will continue to receive 300 Âµg 
b Subjects receiving 10 Âµg who require a dose reduction will receive placebo  
c Restart darbepoetin alfa when Hb < 10.0 g/dL, at next lower PSD 
When darbepoetin alfa therapy is  withheld per the dosing algorithm, placebo will be 
administered.  Once the Hb falls  to < 10.0 g/dL, darbepoetin alfa therapy will be resumed 
at the next lower PSD.  
[IP_ADDRESS].2  Fixed Dose Group  
Subjects randomized to the fixed dose group will receive the same dose as the 
one assigned at the time of randomization for the duration of the treatment period with 
1 exception:  if the Hb is > 12.0 g/dL, darbepoetin alfa  therapy will be withheld and 
placebo administered.  Once the Hb falls to < 10.0 g/dL, darbepoetin alfa therapy will 
resume  at the same dose.   
[IP_ADDRESS]  Missed Doses  
If a subject in either group misses a scheduled dose of investigational product  (defined 
as Q4W Â± 5 days), this dose will not be administered off schedule.  The missed dose 
and reason should be entered into the eCRF .  For the next dosing  visit, the subject 
should return to their  original visit schedule. 
If a subject misses > [ADDRESS_1160308]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 29 of 67 
 6.5 Concomitant Therapy  
Throughout the study, investigators may prescribe any concomitant medications or 
treatments deemed necessary to provide adequate supportive care except for those 
listed in Section 6.8.   
It is recommended that all subjects be iron replete during the study.  Supplemental iron 
therapy should be administered as needed and as tolerated.  The National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelin es recommend 
that TSAT be maintained â‰¥ 20% and fer ritin â‰¥ 100 ng/m L. 
Blood pressure should be monitored and managed as appropriate.  The KDOQI  
guidelines  recommend to target a  SBP < 130 mmHg and a DBP < 80 mmHg . 
6.6 Medical Devices  
The following medical devices will be used in this study and provided by [CONTACT_11337]: 
â€¢ Modified HemoCue Hb 201+ system hemoglobin analyzer  
â€¢ Auto inflate blood pressure monitor  
Medical devices (eg, syringes, sterile needles, alcohol prep pads), that are commercially 
available are not usually provided or reimbursed by [CONTACT_11337].  The investigator  will be 
responsible for obtaining supplies of these devices.  
6.6.1  Modified HemoCue Hb 201+ System Hemoglobin Analyzer  
The HemoCue Hb 201+ system hemoglobin analyzer is a Hb POC  device manufactured 
by [CONTACT_835755].  The device has been modified by [CONTACT_835756].  The modified HemoCue will be  
provided by [CONTACT_835757] . 
Additional details for the modified  HemoCue Hb POC  device may be found in the study 
specific user manual that accompanies the device.  
6.6.[ADDRESS_1160309]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160310] complaint(s) associated with an investigational product or device supplied by [CONTACT_147232].  
6.8 Excluded Treatments During Study Period  
Subjects are prohibited from participating in other interventional studies (eg, studies 
which require medical device use or drug therapy or with protocol required procedures ) 
while  participating in this study.  
Subjects should not receive commercial ESAs while  receiving investigational product 
during the study.  
7. STUDY PROCEDURES  
Screening assessments and study procedures are outlined in this section and in Appendix  A.  The informed consent must be obtained prior to performing any screening 
or study procedures.   
All on -study visits and d osing should be scheduled from Study Day 1.  It is important to 
perform study procedures and obtain samples at the time points outlined in the protocol.  When it is not possible to perform the study visit at the specified time point, the visit may be performed within the acceptable visit window as defined in Section 7.1.  If a study 
visit is missed , subsequent study visits should resume on the original visit schedule.  
Missed assessments at prior visits should not be duplicated at subsequent visits.  
With the ex ception of the screening and rescreen visits, all study procedures for a vis it 
must be c ompleted on the same day.  
It is the responsibility of the investigator to ensure all procedures are performed according to the protocol.  
7.1 General Study Procedures  
Any blood or serum  sample collected according to the Schedule of Assessments 
(Appendix  A) may be analyzed for any of the tests outlined in the protocol and for any 
tests necessary to ensure subject safety .  This includes testing to ensure analytical 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160311],  [COMPANY_010] may do additional testing on 
remaining samples (ie, residual and back -up) as well as those collected for biomarker 
development as described in Section 7.4.  These samples may be used  to investigate 
and better understand CKD , the dose response and/or prediction of response to 
darbepoetin alfa, characterize antibody response, and characterize aspects of the 
molecule (eg, metabolites).  Results from this analysis will be documented and 
maintained, but may not be reported as part of this s tudy.  
The procedures performed at each study visit are outlined below and in Appendix  A. 
Details regarding each type of procedure are provided in Section 7.2.  
7.1.[ADDRESS_1160312] be obtained before completing any other screening procedures.  
After signing the informed consent form, subjects will be screened in order to assess eligibility for study participation.  The screening window is up to 28 days ; subjects must 
complete [ADDRESS_1160313] screening 
visit: 
â€¢ Informed consent  
â€¢ Blood pressure  and pulse 
â€¢ Weight  
â€¢ eGFR , serum creatinine  
â€¢ Hb, using the modified  Hb POC d evice  
â€¢ Serum pregnancy test for all women (except for women who are surgically sterile or 
are at least 1 year postmenopausal)  
â€¢ TSAT, ferritin, iron, total iron binding capacity (TIBC)  
â€¢ Serum vitamin B12 and folate 
Serious adverse events will be collected from  the time the informed consent is signed.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160314] screening visit.  The following procedures will be performed  during the 
second screening visit:  
â€¢ Blood pressure and pulse 
â€¢ Serious adverse event assessment 
â€¢ Hb, using the modified  Hb POC device 
7.1.[ADDRESS_1160315] be registered as screen failed in the IVR/IWR system and subsequently 
registered as a rescreen subject.  Once the subject is registered as rescreened, a new 
28-day screening window will begin.  All  screening procedures will ne ed to be repeated.  
7.1.[ADDRESS_1160316] has met all eligibility criteria, sites will need to 
complete the randomization call in t he IVR/IWR system prior to beginning the Day  1 
evaluations.  All subsequent doses and study visits will be scheduled based on the 
Day 1 date.  
The following procedur es will be completed on Day 1:  
â€¢ Medical and surgical history, including history of transfusions 
â€¢ Physical exam, including height  and weight  
â€¢ Electrocardiogram  
â€¢ Concomitant medications  (as specified in Section  7.2.9 ) 
â€¢ eGFR , serum creatinine 
â€¢ Complete blood count (CBC; results will remain blinded)  
â€¢ TSAT, ferritin, iron, TIBC  
â€¢ Troponin-T 
â€¢ Serum albumin, high sensitivity C-reactive protein ( CRP ) 
â€¢ Reticulocytes  (results will remain blinded)  
â€¢ Blood s amples for biomarkers  
â€¢ Spot urine albumin and creatinine 
â€¢ Anti-erythropoietic protein antibodies  
â€¢ Anti-human leukocyte antigen (HLA) antibodi es 
â€¢ Investigational product administered  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160317] is enrolled, collection of the following will begin:  
â€¢ RBC transfusions, as well as transfusions of other blood- derived products  
â€¢ Endpoint data for adjudication 
â€¢ Hospi[INVESTIGATOR_602], including observational  stays, and emergency department visits  
â€¢ Adverse events  
7.1.4  Treatment Period Evaluations  
[IP_ADDRESS]  Routine Study Visits  
Routine study visits  will occur Q4W , as noted in the Schedule of Assessments 
(Appendix  A), during the treatment period beginning at  week 5 through the week 97 visit.  
On-study visits may be completed within Â± 5 days of the target visit date.  The following 
procedures and data collection will be completed:  
â€¢ At Week 5  
âˆ’ CBC (results will remain blinded)  
âˆ’ TSAT, ferriti n, iron, TIBC  
â€¢ At Week 5 and every 4 weeks  thereafter  
âˆ’ Blood pressure  and pulse 
âˆ’ Concomitant medications (as specified in Section  7.2.9 ) 
âˆ’ RBC transfusions, as well as transfusions of other blood- derived products  
âˆ’ Endpoint data for adjudication 
âˆ’ Hospi[INVESTIGATOR_602] , including observational stays, and emergency department visits  
âˆ’ Adverse event and serious adverse event assessment  
âˆ’ Hb, using the modified  Hb POC d evice  
âˆ’ Investigational product administration 
â€¢ Every 12 weeks  
âˆ’ CBC ( results will remain blinded)  
âˆ’ TSAT, ferritin, iron, TIBC  
âˆ’ Anti-HLA antibodies  
â€¢ Every 24 weeks  
âˆ’ eGFR, serum creatinine 
âˆ’ Blood s amples for biomarkers  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 34 of 67 
 [IP_ADDRESS]  Additional Visits for Blood Pressure Monitoring 
For any subject with a mean SBP â‰¥ 160 mmHg measured during a rout ine study visit, an 
additional blood pressure monitoring visit is required 2 weeks later.  This visit may be 
completed within Â± 5 days of the scheduled visit date.   
For subjects with mean SBP < 160 mmHg an additional study visit for blood pressure monitor ing may also be scheduled 2 weeks after a routine study visit at the discretion of 
the investigator.  This visit may be completed within Â± 5 days of the scheduled visit date.  
The procedures and data collected at blood pressure monitoring visits  will includ e: 
â€¢ Blood pressure and pulse 
â€¢ Concomitant antihypertensive medications  
â€¢ Adverse event and serious adverse event assessment  
The SBP obtained during these visits will be entered into the IVR/IWR system.  
7.1.[ADDRESS_1160318] all End of Study (EOS) evaluations performed as outlined in Section 7.1.7  below.  
7.1.7  End of Study Evaluations 
Subjects will complete an EOS visit at w eek 101 within Â± 5 days  of the target visit date  or 
at early termination.  The following procedures apply to the EOS visit:  
â€¢ Physical examination 
â€¢ Blood pressure and pulse 
â€¢ Weight  
â€¢ Concomitant medications  (as specified in Section  7.2.9 ) 
â€¢ RBC transfusions, as well as transfusions of other blood- derived products  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 35 of 67 
 â€¢ Endpoint data for adjudication 
â€¢ Hospi[INVESTIGATOR_602] , including observational stays , and emergency department visits  
â€¢ Adverse event and serious adverse event assessment  
â€¢ eGFR , serum c reatinine 
â€¢ Hb, using the modified  Hb POC device 
â€¢ Blood s amples for biomarkers  
â€¢ Anti-erythropoietic protein antibodies  
â€¢ Anti-HLA antibodies  
7.[ADDRESS_1160319]â€™s complete medical and surgical history will be obtained on Day [ADDRESS_1160320] of a  follow -up 
examination to monitor for any changes from the Day 1 physical examination.   Any 
clinically significant changes in physical examination per the investigatorâ€™s  opi[INVESTIGATOR_835730]. 
7.2.4  Blood Pressure  and Pulse  
Blood pressure  and pulse will be obtained using an automated blood pressure machine 
provided by [CONTACT_835758] .   
Blood pressure measurements should follow  the recommended technique from the 
American Heart Association ( Pi[INVESTIGATOR_116281], 2005 ).  The blood pressure should be taken 
with the subjectâ€™s arm  supported at heart level using the appropriate sized cuff with the 
subject seated comfortably in a chair with their back supported and both feet on the ground.   Subjects should be resting quietly for at least [ADDRESS_1160321]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160322] 1 minute apart  during 
subsequent visits .  
If the mean SBP is > 140 mmHg or the mean DBP is > 90 mmHg at any study visit, additional information regarding the management of hypertension (eg, modification 
of antihypertensive medications) will be collected in the eCRF. 
7.2.[ADDRESS_1160323]â€™s Hb is < 8.0 g/dL or > 13.0 g/dL, the investigator will be notified by [CONTACT_21925]/IWR system so that he/she may follow -up as clinically indicated.  
In addition, CBCs will be collected as specified in the Schedule of Assessments 
(Appendix  A).  The results of the CBC will remain blinded.  
7.2.[ADDRESS_1160324] is on-study  will be recorded on the RBC transfusion eCRF.   Information 
regarding the context surrounding transfusions will be collected at each study visit including units of RBCs transfused , the transfusion setting (eg, dialysis center, intensive 
care unit, emergency department), and clinical events (eg, bleeding, surgery) .  This 
informatio n will be  reviewed by [CONTACT_835759] C ommittee (CEC). 
7.2.[ADDRESS_1160325] is on-study  will be r ecorded on the eCRF, including the primary 
reason for the visit/stay . 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160326] will be documented as a protocol deviation.  For subjects who 
receive commercial ESA s, the name [CONTACT_11889], dose, route and dates of 
administration will be collected. 
7.2.10  Electrocardiogram  (ECG)  
A standard [ADDRESS_1160327]â€™s source documents.  At the request of the sponsor, the original 
ECG tracing may be made available to [COMPANY_010].  
7.2.[ADDRESS_1160328]â€™s source documents.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 38 of 67 
 Clinical events  to be collected for adjudication include:  
â€¢ All-cause mortality  
â€¢ Stroke, TIA, MI, decompensated heart failure, thromboembolism, and vascular 
access throm bosis  
â€¢ The clinical context surrounding RBC transfusions  
7.2.[ADDRESS_1160329] administration.  The date and time of blood and urine collection will be recorded in the source documents at the site.  
Table 2  below outlines the specific analytes for serum chemistry, iron and other testing 
to be conducted on blood and urine samples.  
Table 2 .  Analyte Listing 
Chemistry  Urine  Hematology  Other  
Creatinin e  Spot albumin  White blood cell count (WBC)  Serum pregnancy test  
Albumin  Spot creatinine  RBC  eGFR  
   Hb High sensitivity CRP  
Iron  Hematocrit (HCT)  Folate  
TSAT    Platelets  Vitamin B12  
Ferritin   Mean corpuscular hemoglobin (MCH)  Troponin -T 
Iron  Mean corpuscular hemoglobin 
concentration (MCHC)  Anti-erythropoietic 
protein antibodies  
TIBC   Mean corpuscular volume (MCV)  Anti-HLA antibodies  
  Red cell distribution width (RDW)   
   Mean platelet volume (MPV)   
   Reticulocytes   
7.[ADDRESS_1160330]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 39 of 67 
 will also be tested for neutralizing antibodies and may be further characterized for 
quantity/titer, isotype, affinity and presence of immune complexes.  Additional blood 
samples may be obtained to rule out anti -erythropoietic protein antibodies during the 
study.    
Subjects who test positive for neutralizing antibodies at the final scheduled study visit will 
be asked to return for additional follow -up testing.  This testing should occur 
approximately every 12 weeks starting from when the site has been notified of the 
positive result, until:  (1)  neutralizing antibodies are no longer detectable or (2)  the 
subject has been followed for a period of at least 1 year ( Â± 4 weeks).  More frequent 
testing (eg, Q4W ) or testing for a longer period of time may be requested in the event of 
safety -related concerns.  Follow -up testing will not be required where it is established 
that the subject did not receive darbepoetin alfa . 
Subjects who test positive for binding, non- neutralizing antibodies and have clinical 
sequelae that are considered potentially related to an anti -erythropoietic protein antibody 
response may also be asked to return for additional follow -up testing.  
7.3.[ADDRESS_1160331] foreign antigens, and in particular foreign HLA.  The detection of anti -HLA antibodies  (allosensitization) has changed dramatically 
over the last few years, becoming much more sensitive and more specific 
(Murphey  and Forsthuber, 2008).  Given the rapid innovation in the determination of 
allosensitization, samples  collected for anti -HLA antibodies  during the course of the trial 
will be stored until the completion of the study.   Anti-HLA antibodies  will then be 
measured using the state- of-the-art and accepted methods at that time.  
7.[ADDRESS_1160332]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 40 of 67 
 every 24 weeks thereafter for the duration of the study.   Refer to the l aboratory manual 
for detailed collection and handling procedures for all biomarker development samples.  
Sample Storage and Destruction  
These biomarker development samples  and any other components from the cells may 
be stored for up to 20 years from the end of the study to research scientific questions 
related to nephrology  and/or darbepoetin alfa .  The subject retains the right to request 
that the sample material be destroyed at any time by [CONTACT_59554].  The sponsor will be the exclusive owner of any data, discoveries, or derivative materials from the sample materials and is responsible for the destruction of the sample(s) at the request of the subject through the principal investigator [INVESTIGATOR_835731] (eg, the scientific rationale for 
experimentation with a certain sample type no longer justifies keepi[INVESTIGATOR_21878]).  
Following the request from the subject, the principal investigator [INVESTIGATOR_835732].  If a commercial product is developed from this research project, the sponsor will own the commercial product.  The subject will have no commercial rights to such product and will have no commercial rights to the data, information, discoveries, or derivative materials gained or produced from the sample.  
8. REMOVAL AND REPLACEMENT OF SUBJECTS  
8.[ADDRESS_1160333] the right to withdraw from the study at any time and for any reason without prejudice to his or her future medical care by [CONTACT_8018]. 
Subjects (or a legally acceptable representative) can decline to continue receiving 
investigational product at any time during the course of the study.  If this occurs, the 
investigator is to discuss with the subject the appropriate procedures for discontinuation from investigational product and must discuss with  the subject the options for 
continuation of the schedule of  assessments and collection of data, including endpoints 
and adverse events.  These subjects, as well as those who have stopped receiving investigational product for other reasons (eg, initiation of dialysis ), are encouraged to 
continue the schedule of study visits .  If the subject is unable or unwilling to continue the 
schedule of visits : 
â€¢ At a minimum, subjects should be followed for the occurrence of RBC transfusions 
and collection of endpoint data for adjudication 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 41 of 67 
 â€¢ The investigator must  document the change in schedule of assessments  and the 
level of  follow -up the subject is permitting:  in person, by [CONTACT_756]/mail, through 
family/friends, in correspondence/communication with other physicians, and/or from 
review of the medical records  
Withdrawal of consent  for a study means that the subject does not wish to receive 
further investigational treatment and does not wish to or is unable to continue further 
study participation; subject data up to withdrawal of consent will be included in the analysis of the study , and where permitted, publically available data can be included 
after withdrawal of consent .  The investigator will discuss with the subject appropriate 
procedures for withdrawal from the study.   
Should a subject (or a legally acceptable representative) request or decide to withdraw 
from the study, all efforts will be made to complete and report the observations as 
thoroughly as possible up to the date of withdrawal.  All information should be reported on the applicable eCRFs.   
Reasons for removal from protocol -required  investigational product  or procedural 
assessments include:  
â€¢ subject request to end investigational product administration  
â€¢ pregnancy in a female subject (report on Pregnancy Notification Worksheet; 
see Appendix  D) 
â€¢ safety concern (eg, due to an adverse event) 
â€¢ initiation of dialysis or receipt of a kidney transplant  
â€¢ lack of efficacy  (eg, need for a commercial ESA regularly)  
Reasons for removal of a subject from the study include:  
â€¢ withdrawal of consent  from the study  
â€¢ death  
â€¢ lost to follow -up 
â€¢ administrative decision by [CONTACT_11337]  
8.[ADDRESS_1160334]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160335]â€™s medical record.   
The definition of adverse events includes worsening of a pre- existing medical condition.  
Worsening indicates the pre- existing medical condition (eg, diabetes, migraine 
headaches, gout) has increased in severity, frequency, and/or duration, and/or has an 
association with a significantly worse outcome.  A pre- existing condition that has not 
worsened during the study and involves an intervention while on- study, such as elective 
cosmetic surgery or a medical procedure , is not considered an adverse event.  
An adverse device effect is any adverse event related to the use of a medical device.  
Adverse device effects include adverse events resulting from insufficient or inadequate 
instructions for use, adverse events resulting from any malfunction of the device(s) , or 
adverse events resulting from use error or from intentional misuse of the device(s). 
9.1.[ADDRESS_1160336]  are reported using the applicable e CRF 
(eg, Adverse Event Summary  eCRF) .  
The investigator must assign the following adverse event attributes:  
â€¢ Adverse event diagnosis or syndrome(s), if known (if not known, signs or symptoms),  
â€¢ Dates of onset and resolution,  
â€¢ Severity [and/or toxicity per protocol],  
â€¢ Assessment of relatedness to darbepoetin alfa,  and 
â€¢ Action taken  
The adverse event toxicity grading scale used will be the [COMPANY_010] adverse event standard 
grading score.   The toxicity  grading scale used in this study is described in Appendix  B. 
The investigator must assess whether the adverse event is possibly related to 
darbepoetin alfa.  This relationship is indicated by a â€œyesâ€ or â€œnoâ€ response to the 
question:  Is there a reasonable possibility that the event may have been caused by [CONTACT_835760]?  
The investigator must assess whether the adverse event is possibly related to a device.   
This relationship is indicated by a â€œyesâ€ or â€œnoâ€ response to the question:  Is there a 
reasonable possibility that the event may have been caused by a device? 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160337] assess whether the serious  adverse event is possibly related to 
any study -mandated screening procedure.  This relationship is indicated by a â€œyesâ€ or 
â€œnoâ€ response to the question:  â€œIs there a reasonable possibility that the event may be 
related to screening procedures?â€ 
The investigator must assess whether the adverse event is possibly related to any 
study -mandated activity or procedure.  This relationship is indicated by a â€œyesâ€ or â€œnoâ€ 
response to the question:  â€œIs there a reasonable possibility that the event may have 
been caused by a study activity/procedure?â€ 
The investigator is responsible for reviewing laboratory test results and determining 
whether an abnormal value in an individual study subject represents a clinicall y 
significant change from the subjectâ€™s baseline values.  In general, abnormal laboratory findings without clinical significance (based on the investigator's judgment) should not be recorded as adverse events.  However, laboratory value changes that require treatment or adjustment in current therapy are considered adverse events.  Where applicable, 
clinical sequelae (not the laboratory abnormality) should be recorded as the adverse 
event.  
The investigatorâ€™s clinical judgment will be used to determine whether a subject should be removed from treatment or from the study due to an adverse event.  A subject, or subjectâ€™s parent/legal guardian, may also voluntarily withdraw from treatment due to an adverse event.  If the subject requests to withdraw consent  for further participation in the 
study , the subject should be encouraged to undergo, at a minimum, an end- of-study 
assessment.   
9.[ADDRESS_1160338] 1 of the following serious criteria: 
â€¢ fatal 
â€¢ life threatening (places the subject at immediate risk of death)  
â€¢ requires in -patient hospi[INVESTIGATOR_1081] 
â€¢ results in persistent or significant disability/incapacity  
â€¢ congenital anomaly/birth defect 
â€¢ other medically important serious event  
An adverse event would meet the criterion of â€œrequires hospi[INVESTIGATOR_059]â€, if the event 
necessitated an admission to a health care facility (eg, overnight stay).   
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 44 of 67 
 If an investigator considers  an event to be clinically important, but it does not meet any 
of the serious criteria, the event could be classified as a serious adverse event under the 
criterion of â€œother medically important serious eventâ€.  Examples of such events could include allergic bronchospasm, convulsions, blood dyscrasias,  or events that necessitate 
an emergency room visit, outpatient surgery, or urgent intervention.  
9.2.[ADDRESS_1160339]â€™s medical record and are submitted to [COMPANY_010].  Any serious adverse events 
with a fatal outcome (regardless of possible relationship to investigational product) 
occurring through the end of the subjectâ€™s participation on the study are to be reported to 
[COMPANY_010] .  This would include subjects  who have been re moved from investigational 
product and continued on-study .   
After the protocol -required reporting period defined above, the investigator does not 
need to actively monitor subjects for serious adverse events.  However, if the investigator becomes aware of a serious adverse event after this protocol -required 
reporting period, the investigator will report the event to [COMPANY_010] within 24 hours following 
the investigatorâ€™s knowledge of the event.  Serious adverse events reported outside of the protocol -required re porting period will be captured within the safety database as 
clinical trial cases for the purposes of expedited reporting.  
The serious adverse event must be submitted to [COMPANY_010] within 24 hours following the 
investigatorâ€™s knowledge of the event via the applicable eCRF.  If the electronic data capture (EDC) system is unavailable to the site staff to report the Serious Adverse Event, the information is to be reported to [COMPANY_010] via an electronic Serious Adverse Event (eSAE) Contingency Report Form within 24 hours of the investigatorâ€™s knowledge of the event.  See  Appendix  C for a sample of the Serious Adverse Event 
Worksheet/eSAE Contingency Report Form.  When the first notification of a Serious Adverse Event is reported to [COMPANY_010] via the eSAE Contingency Report Form, the data 
must be entered into the EDC system when the system is again available.  
The investigator must assess whether the serious adverse event is possibly related to any study -mandated activity or procedure.   This relationship is indicated by a â€œyesâ€ or 
â€œnoâ€ response to the question:  â€œIs there a reasonable possibility that the event may have been caused by a study activity/procedureâ€?  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160340] be consistent with that recorded on t he applicable e CRF 
(eg, Adverse Event Summary eCRF).  
If a subject is permanently withdrawn from the study because of a serious adverse event, this information must be submitted to [COMPANY_010]. 
To comply with worldwide reporting regulations for serious adverse ev ents, the treatment 
assignment of subjects who develop serious, unexpected, and related adverse events 
may be unblinded by [CONTACT_21960].  Investigators 
will receive notification of related serious advers e events reports  sent to regulatory 
authorities in accordance with local requirements.   
[COMPANY_010] will report adverse events and/or suspected unexpected serious adverse 
reactions as required to regulatory authorities, investigators/institutions, and IRBs/IECs in compliance with all reporting requirements according to local regulations and good clinical practice.  
The investigator is to notify the appropriate IRB/ IEC of serious adverse events occurring 
at the site and other adverse event reports received from [COMPANY_010], in accordance with local procedures and statutes.   
9.[ADDRESS_1160341] and for 4 weeks  after end of treatment , the 
pregnancy should be reported to [COMPANY_010]â€™s global Pregnancy Surveillance Program  within 
24 hours of the investigatorâ€™s knowledge of the event of a pregnancy.  Report  a 
pregnancy on the Pregnancy Notification Worksheet (Appendix  D).  The Pregnancy 
Surveillance Program will seek to follow the pregnant woman throughout her pregnancy and her baby [CONTACT_8622] [ADDRESS_1160342] is taking protocol -required therapi[INVESTIGATOR_835733] 4 weeks after end of treatment, the lactation case should be reported to [COMPANY_010]â€™s 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 46 of 67 
 global Lactation Surveillance Program (LSP) within  24 hours of the investigatorâ€™s 
knowledge of the lactation case.  Report a lactation case on the Lactation Notification 
Workshee t (Appendix  E). 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints, Subsets, and Covariates  
10.1.1  Study Endpoints  
Primary endpoint  
â€¢ Receipt of 1 or more  RBC transfusion  
Secondary endpoints  
â€¢ Total number of units of RBC transfused  
â€¢ Time to first RBC transfusion  
â€¢ Average achieved Hb concentration while receiving investigational product  
â€¢ Cumulative dose of darbepoetin alfa  
Safety endpoints 
â€¢ Time to major clinical events:  
âˆ’ Composite of all-cause mortality and the occurrence of major cardiov ascular 
events (stroke, myocardial infarction, and decompensated heart failure)  
âˆ’ Composite of all -cause mortality, stro ke or myocardial infarction, ie,  major 
adverse cardiovascular events ( MACE ) 
âˆ’ All-cause mortality  
âˆ’ Cardiovascular mortality  
âˆ’ Stroke 
âˆ’ Myocardial  infarction 
âˆ’ Decompensated heart failure 
âˆ’ Thromboembolic events  
âˆ’ Vascular access thrombosis  
â€¢ Adverse events  
â€¢ Blood pressure and pulse 
â€¢ Anti-erythropoietic protein antibodies  
Exploratory endpoints â€¢ Darbepoetin alfa dose received at each study visit  
â€¢ Hb concentration at each study visit  
â€¢ Hb concentration change from baseline at each study visit  
â€¢ Time to first Hb concentration â‰¥ 10.0 g/dL  
â€¢ Proportion of Hb measurements â‰¥ 10.0 g/dL  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 47 of 67 
 â€¢ Hb rate of change in a 4 week interval at each study visit  
â€¢ Hb variability, defined as the  intrasubject standard deviation over a 6 month rolling 
window 
â€¢ Initial Hb respons e, defined as the change of Hb concentration from baseline at 
week  5 
â€¢ Darbepoetin alfa dose over time by [CONTACT_835737] 
â€¢ Hb over time by [CONTACT_835737]  
â€¢ Number of days hospi[INVESTIGATOR_057]  
â€¢ Anti-HLA antibodies  
10.1.[ADDRESS_1160343].  Subjects will be analyzed according to their randomized 
treatment assignment.  
10.1.3  Subgroups and Covariates  
Subgroups and covariates to be considered include the stratification factors used 
at randomization, and  the following baseline factors: age, sex, race, baseline 
Hb concentration and baseline eGFR.   Subgroups are defined as  
â€¢ Age: < 65, â‰¥ 65 and < 75, â‰¥ 75 years  
â€¢ Gender: Female, Male  
â€¢ Race: White, Black, Other  
â€¢ Baseline Hb concentrations: <9.0, 9.0 â€“ < 9.5, 9.5 â€“ < 10.0 g/dL  
â€¢ Baseline eGFR: < 30.0, â‰¥ 30.0 mL/min/1.73m2 
Additional analyses may be performed if other prognostic factors emerge in this study or 
in this population.  
10.2 Sample Size Considerations  
The objective of the study is to provide estimations with acceptable precision.  Thus, t he 
sample size is chosen to ensure that the width of the 95% confidence interval ( CI) for the 
proportion of subject s who receive at least 1 RBC transfusion in each treatment group 
will be â‰¤ 10% (ie,  Â± 5% around the point estimate), assuming the proportion to be 25%.  
The choice of the precision of the estimated transfusion rate is based on clinical 
relevance and experience.   The estimated proportion of 25% of subjects  receiving at 
least [ADDRESS_1160344] hoc analyses in both treatment groups of 
TREAT of subjects who met the eligibility criteria for this study ([COMPANY_010] data on file)  and 
transfusion rates observed in other  studies (Provenzano et al, 2004; Lawler  et al, 2010).  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 48 of 67 
 To ensure the 95% CI with a width  of â‰¤ 10%, 300 subjects per group will be needed to 
enroll into the study.  In order to ensure this precision can be maintained for sensitivity 
analyses, 20% drop out  is accounted for, and  enrollment of  375 subjects per treatment 
group is planned .  This to tal sample size of 750 subjects will also ensure that the width 
of the 95% CI of the difference in transfusion incidence rates will be â‰¤ 14% 
(ie, Â± 7% around the point estimate), assuming the proportion of subjects receiving at 
least 1 RBC transfusion duri ng the study in both treatment groups is 25%.   All 
confidence interval s are derived using normal approximation.  
10.[ADDRESS_1160345] treatment assignments will be maintained by [CONTACT_21925]/ IWR system.  
Only t he Data Monitoring Committee (DMC)  and the supporting independent biostatistics 
group will have access to unblinded data .  Members of the [COMPANY_010] study team will not 
have access to unblinded data until the study is unblinded for the final analysis.   
The external, independent biostatistics group will provide unbl inded results, including 
aggregate and subject level data, to the DMC  for regular data reviews.  The role of the 
DMC is discussed in Section 10.4.  Any unplanned unblinding occurring during the study 
period will be documented and reported in the final clinical study report.  
[COMPANY_010] s taff from the Clinical Supply Chain  Management  and Biological Sample 
Management  departments will not be blinded to the treatment assignments in this study.  
10.[ADDRESS_1160346] a reassess ment of  the study assumptions (eg, transfusion rate) based on blinded 
aggregated data  and revise the sample size in order to ensure that the desired precision 
of transfusion rate estimates can be achieved.  
An independent, external  DMC will review unblinded study data throughout the duration 
of the study  and may request additional data.  If warranted, the  DMC can recommend 
modifying or stoppi[INVESTIGATOR_10098] , or suspending enrollment .  This recommendation can 
be based on any safety  concerns , lack of efficacy/futility, or preponderance of early 
evidence of efficacy .  The DMC will convene approximately once every 3-6 months .  The 
DMC will oversee an interim analysis to assess the totality of the data , which will occur when approximately 33% of subjects have completed [ADDRESS_1160347]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 49 of 67 
 10.5 Planned Methods of Analysis  
10.5.1  General Approach/Consi derations  
Descriptive statistics will be presented for all endpoints by [CONTACT_1570].  For 
continuous variables, these include number of observations, mean, standard error (SE) and/or standard deviation (SD), median, 25
th percentile (Q1), 75 th percentil e (Q3), 
minimum and maximum.  For categorical variables, the frequency and percentage are presented.  For time to event endpoints: Kaplan- Meier curves, Kaplan- Meier percentiles, 
the number of subjects censored, and the number of subjects with events  will b e 
summarized .  Confidence intervals will be constructed as 2-sided at the 95% level.   
Summaries of laboratory data, Hb and dose related parameters , and vital signs will be 
completed using the full analysis set, limited to measurements obtained while the subject 
is receiving the investigational product.  
10.5.2  Analysis of Key Study Endpoints  
[IP_ADDRESS]  Efficacy Endpoints  
The primary analysis  of the primary endpoint will be conducted using the full analysis 
set.  The evaluation period will begin  from the date of randomization and subjects will be 
censored at the last dose of investigational product  plus 3 months  or end of study, 
whichever is earlier  (on-treatment approach).  For the primary endpoint, the proportion of 
subjects in each treatment group receiving at least 1 RBC tr ansfusion during the 
evaluation period will be presented with 2-sided 95%  CIs.  The difference in proportions 
between treatment groups and the relative risk ratio will be described with 2-sided 
95% CIs.  Confidence intervals will be derived using normal approximation. 
The primary analysis will be repeated  by [CONTACT_835761], and also by [CONTACT_835762], gender, race, baseline Hb concentrations 
and baseline eGFR.  
Sensitivity analys es of the primary endpoint  will be repeated using all randomized 
subjects with the evaluation period beginning at  the date of randomization and subjects 
will be censored at the end of study (on- study approach).   
Sensitivity analyses will be performed to assess the impact of potential differential follow up on the primary endpoint .  Exposure- adjusted subject incidence of receiving at least 
1 RBC transfusion will be calculated with 95% CI using Chi -square approximation to the 
Poisson distribution for both on -treatment and on -study approaches.   Other sensitivity 
analyses, such as completer analyses for investigational product and study, may be performed as appropriate.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160348] incidence.  
[IP_ADDRESS]  Secondary Endpoints  
Total number of units of RBC transfused per subject will be described for each treatment 
group, and will be a nalyzed using a negative binomial regression model which will 
include the stratification factors used at randomization.  As a sensitivity analysis, 
exposure adjusted event incidence of total number of units RBC transfused will be 
presented with 95% CI using Chi -square approximation to the Poisson distribution .  
These analyses will be performed using both on -treatment and on -study approaches.  
Time to first RBC transfusion using both on- treatment and on -study approaches will be 
analyzed by [CONTACT_835763]- Meier curves, K aplan- Meier percentiles, 
the number of subjects censored, and the number of subjects transfused.   A supportive 
analysis will be performed using Cox proportional hazards model ( Cox, 1972) stratified 
by [CONTACT_835764] .  The hazard ratio and its corresponding 95% CI will be estimated.  
Average achieved Hb concentration while receiving investigational product will be described as average Hb using the area under the curve (A UC) method.   The median of 
the difference in achieved Hb concentration (Hodges â€“Lehmann estimate) between 
treatment groups will be calculated and 2 -sided 95% confidence limits  will be derived by 
[CONTACT_2329] a nonparametric Wilcoxon rank -sum statistic ( Holander and Wolfe, 1973).  
Cumulative doses of darbepoetin alfa adjusted for investigation product exposure time 
will also be summarized, and the median of the difference (Hodges â€“Lehmann estimate) 
between treatment groups will be calculated and 2 -sided 95% confidence  limits  will be 
derived by [CONTACT_2329] a nonparametric Wilcoxon rank -sum statistic.  
[IP_ADDRESS]  Safety Endpoints 
Time to adjudicated event endpoints, such as composite endpoints of mortality and CV 
morbidity, all-cause mortality, and fatal and non -fatal CV events, will be summarized by 
[CONTACT_835763]- Meier curves, Kaplan- Meier percentiles, the number 
of subjects censored, and the number of subjects with events.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160349] will be tabulated by [CONTACT_835765].  Subgroup analyses (by [CONTACT_551], race, and gender) will be presented for all adverse events.  
Vital signs at each study visit will be summarized descriptively by [CONTACT_1570].  Average blood pressure on treatment will be described as average value using the 
AUC method , and medication changes secondary to elevated blood pressure will be 
summarized descriptively in each treatment group. 
The incidence and percentage of subjects who develop anti -erythropoietic protein 
antibodies (binding and if positive, neutralizing) at any time will be tabulated by [CONTACT_6490].  
[IP_ADDRESS]  Explorato ry Endpoints 
All exploratory endpoints, except otherwise mentioned in this section,  will be described  
by [CONTACT_81591] .  In addition to Hb concentration and change from baseline at 
each study visit, the subgroups of Hb concentrations , will also be p resented.  
Number of days hospi[INVESTIGATOR_835734]-treatment approach. 
Achieved Hb concentration and cumulative dose over time will be summarized by [CONTACT_835766].  
Anti-HLA antibodies over time will be tabulated by [CONTACT_81591].  
10.5.[ADDRESS_1160350]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 52 of 67 
 group.   The analyses of laboratory parameters will include summary statistics at the 
scheduled visit by [CONTACT_1570].  
11. REGULATORY OBLIGATIONS  
11.1 Informed Consent  
An initial generic informed consent form  (ICF)  is provided for the investigator to prepare 
the informed consent document to be used at his or her site.  Updates to the template 
will be communicated by [CONTACT_246529].  The written informed consent document should be prepared in the language(s) of the potential patient population.  
Before a subjectâ€™s participation in the clinical study, the investigator is responsible for obtaini ng written informed consent from the subject after adequate explanation of the 
aims, methods, anticipated benefits, and potential hazards of the study and before any protocol specific  screening procedures or any investigational products are administered.   
The investigator is also responsible for asking the subject if the subject has a primary care physician and if the subject agrees to have his/her primary care physician informed of the subjectâ€™s participation in the clinical study.  If the subject agrees to such notification, the investigator shall inform the subjectâ€™s primary care physician of the subjectâ€™s participation in the clinical study.  If the subject does not have a primary care 
physician and the investigator will be acting in that capacity, the investigator should 
document such in the subjectâ€™s medical record .  The acquisition of informed consent and 
the subjectâ€™s agreement or refusal of his/her notification of the primary care physician should be documented in the subjectâ€™s medical records, and the informed consent form should be signed and personally dated by [CONTACT_506215].  The original signed informed consent form should be retained in accordance with institutional policy, and a copy of the signed consent form should be provided to the subject.  
If a potential subject is illiterate or visually impaired and does not have a legally 
acceptable representative, the investigator must provide an impartial witness to read the 
informed consent  form to the subject and must allow for questions.  Thereafter, both the 
subject and the witness must sign the informed consent form to attest that informed consent was freely given and understood.    
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 53 of 67 
 11.2 Independent  Ethics Committee/Institutional Review Board  
A copy of the protocol, proposed informed consent form, other written subject 
information, and any proposed advertising material must be submitted to the IEC/IRB  for 
written approval.  A copy of the written approval of the protocol and ICF must be 
received by [CONTACT_835767]. 
The investigator must submit and, where necessary, obtain approval from the IEC/IRB  
for all subsequent protocol amendments and changes to the informed consent 
document.  The investigator should notify the IEC/IRB of deviations from the protocol or 
serious adverse events occurring at the site and other adverse event reports received from [COMPANY_010], in accordance with local procedures.  
The investigator will be r esponsible for obtaining annual IEC/IRB  approval  /renewal 
throughout the duration of the study.  Copi[INVESTIGATOR_1093] i nvestigatorâ€™s reports and the 
IEC/IRB  continuance of approval must be sent to [COMPANY_010].  
11.[ADDRESS_1160351]â€™s confidentiality is maintained:   
â€¢ On the eCRFs or other documents submitted to [COMPANY_010], subjects should be identified 
by a subject identification number only, with a complete and accurate date of birth on 
the demographics eCRF.   
â€¢ For Serious Adverse Events reported to [COMPANY_010] subjects should be identified by [CONTACT_835768], date of birth, and a subject identification number.   
â€¢ Documents that are not for submission to [COMPANY_010] (eg, signed informed consent forms) should be kept in strict confidence by [CONTACT_093].  
In compliance with Federal regulations/International Conference on Harmonisation ( ICH) 
Good Clinical Practice ( GCP ) Guidelines,  it is required that the investigator and 
institution permit authorized representatives of the company, of the regulatory agency(s), 
and the IEC/IRB  direct access to review the subjectâ€™s original medical records for 
verification of study related procedures and data.  Direct access includes examining, 
analyzing, verifying, and reproducing any records and reports that are important to the 
evaluation of the study.  The investigator is obligated to inform and obtain the consent of the subject to permit named representatives to have access to his/her study  related 
records, including personal information, without violating the confidentiality of the subject.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 54 of 67 
 11.4 Investigator Signatory Obligations  
Each clinical study report should be signed by [CONTACT_1720], in the case of 
multicenter studies, the coordinating investigator.  
The coordinating investigator, identified by [CONTACT_11337], will either be:  
â€¢ a recognized expert in the therapeutic area  
â€¢ an investigator who provided significant contributions to either the design or 
interpretation of the study  
â€¢ an investigator contributing a high number of eligible subjects  
12. ADMINISTRATIVE AND LEGA L OBLIGATIONS  
12.[ADDRESS_1160352] be obtained.  The 
IEC/IRB  must be informed of all amendments and give approval.  The investigator  must  
send a copy of the approval letter from the IEC/IRB  to [COMPANY_010].  
[COMPANY_010] reserves the right to terminate the study at any time.  Both [COMPANY_010] and the 
investigator reserve the right to terminate the investigatorâ€™s participation in the study 
according to the study contract.  The investigator should notify the IEC/IRB  in writing of 
the studyâ€™s completion or early termination and send a copy of the notification to [COMPANY_010] . 
Subjects may be eligible for continued treatment with [COMPANY_010] investigational product by 
[CONTACT_21970]â€™s regulatory mechanism.  However, [COMPANY_010] reserves the unilateral right, at its sole discretion, to determine whether to supply [COMPANY_010] investigational product, and by [CONTACT_21971], after termination of the trial and before it is available commercially.  
12.[ADDRESS_1160353] of appropriately qualified persons to whom he/she has delegated study duties.  All persons authorized to make entries and/or corrections on eCRFs will be included on the [COMPANY_010] Delegation of Authority Form.  
Source documents are original documents, data, and records from which the subjectâ€™s eCRF data are obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence. 
In this study, the ETO System captures the following data points and these are 
considered source data:   hemoglobin.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 55 of 67 
 The investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study related  (essential) documentation, suitable for 
inspection at any time by [CONTACT_21972]/or applicable regulatory authorities.  Elements should include:  
â€¢ Subject files containing completed eCRF,  informed consent forms, and subject 
identification list  
â€¢ Study files containing the protocol with all amendments, investigatorâ€™s brochure, 
copi[INVESTIGATOR_21892], and all correspondence to and from the IEC/IRB 
and [COMPANY_010]  
â€¢ If kept, proof of receipt/delivery sheet, Investigational Product Accountability Record, 
Return of Investigational Product for Destruction, Final Investigational Product 
Reconciliation Statement (if applicable), and all drug related  correspondence 
In addition, all original source documents supporting entries in the eCRFs must be 
maintained and be readily available.  
Retention of study documents will be governed by [CONTACT_21973].  
12.[ADDRESS_1160354], inspecting the various records of the clinical study (eg, eCRFs and other 
pertinent data) provided that subject confidentiality is respected.  
The [COMPANY_010] monitor is responsible for verifying the eCRFs at regular intervals throughout 
the study to verify adherence to the protocol; completeness, accuracy, and consistency 
of the data; and adherence to local regulations on the conduct  of clinical research.  The 
monitor should have access to subject medical records and other study related records 
needed to verify the entries on the eCRFs.  
The investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing eCRFs, 
are resolved.  
In accordance with ICH GCP and the sponsorâ€™s audit plans, this study may be selected for audit by [CONTACT_21975]â€™s Global Compliance Auditing function (or designees).  Inspection of site facilities (eg, pharmacy, drug storage areas, laboratories) 
and review of study related records will occur to evaluate the study conduct and 
compliance with the protocol, ICH GCP, and applicable regulatory requirements.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 56 of 67 
 Data capture for this study is planned to be electronic:  
â€¢ All source documentation supporting entries into the eCRFs must be maintained and 
readily available.  
â€¢ Updates to eCRFs will be automatically documented through the softwareâ€™s â€œaudit 
trailâ€.  
â€¢ To ensure the quality of clinical data across all subjects and sites, a clinical data 
management review will be performed on subject data received at [COMPANY_010].  During 
this review, subject data will be checked for consistency, omissions, and any 
apparent discrepancies.  In addition, the data will be reviewed for adherence to the 
protocol and GCP.  To resolve any questions arising from the clinical data 
management review process, data queries will be created in the EDC system 
database for site resolution and closed by [CONTACT_835769].  
â€¢ The principal investigator [INVESTIGATOR_835735].  This signature [CONTACT_789460] [INVESTIGATOR_835736], the data queries, and the 
site notifications, and agrees with the content.  
[COMPANY_010] (or designee) will perform self -evident corrections to obvious data errors in the 
clinical trial database, as documented in the Study Specific Self Evident Corrections 
Plan.  Examples of obvious data errors that may be corrected by [CONTACT_11337] (or designee) include deletion of obvious duplicate data (eg, same results sent twice with the same date with different visit â€”week 4 and early termination) and clarifying â€œother, specifyâ€ if 
data are provided (eg, race, physical examination).   Each investigative site will be 
provided a list of the types of corrections applied to study data at the initiation of the trial and at study closeout.   
12.[ADDRESS_1160355] use vocabulary and language that are clearly understood.  Consult the country 
specific  requirements for language requirements.  
12.5 Publication Policy  
To coordinate dissemination of data from this study, a publication committee consisting  
of members of the executive committee  and appropriate [COMPANY_010] staff  will be formed , the 
governance and responsibilities of which are set forth in a Publication Charter .  The 
committee is expected to solicit input and assistance from other investigators and to 
collaborate with authors and [COMPANY_010] staff as appropriate as defined in the Publication 
Charter .  Membership on the committee (both for executive committee members  and 
[COMPANY_010] staff) does not guarantee authorshipâ€”the criteria described below should be met for every publication.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 57 of 67 
 Authorship of any publications resulting from this study will be determined on the basis 
of the International Committee of Medical Journal Editors (ICMJE)  
Recommendations for the Conduct, Reporting, Editing and Publication of 
Scholarl y Work in Medical Journals , which states:  
â€¢ Authorship credit should be based on (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the 
article or revising it critically for important intellectual content; (3) final approval of the version to be published; (4) and agreement to be accountable for all aspects of 
the work in ensuring that questions related to the accuracy or integrity of any 
part of the work are appropriately investigated and resolved.  Authors should 
meet conditions 1, 2, 3, and 4. 
â€¢ When a large, multicenter group has conducted the work, the group should identify 
the individuals who accept direct responsibility for the manuscript.  These individuals 
should fully meet the criteria for authorship defined above.  
â€¢ Acquisition of funding, collection of data, or general supervision of the research 
group, alone, does not justify authorship.  
â€¢ All persons designated as authors should qualify for authorship, and all those who 
quali fy should be listed.  
â€¢ Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.  
All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) 
based on this study must be submitted to [COMPANY_010] for corporate review.  The Clinical 
Study Agreement among the institution, principal investigator, and [COMPANY_010] will detail the procedures for, and timing of, [COMPANY_010]â€™s review of publications.  
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 58 of 67 
 13. REFERENCES  
Al Ahmad A, Rand WM, Manjunath G, et al.  Reduced kidney function and anemia as 
risk factors for mortality in patients with left ventricular dysfunction.  J Am Coll Cardiol.  
2001;38:955 -962. 
Astor BC, Muntner P, Levin A, Eustace JA, Coresh J.  Association of kidney function 
with anemia.  Arch Intern Med.  2002;162:1401- 4018. 
Busch MP, Kleinman SH, Nemo GJ .  Current and emerging infectious risks of blood 
transfusions .  JAMA.   2003;289:[ADDRESS_1160356].   Regression models and life- tables (with discussion).  Journal of Royal 
Statisti cal Society .  1972;B,34:187- 220. 
Collins AJ.  The hemoglobin link to adverse outcomes.  Adv Stud Med.   
2003;3:S194 -S197.  
Darbepoetin alfa  Investigatorâ€™s Brochure.  Thousand Oaks, CA:  [COMPANY_010] Inc.  
Despotis GJ, Zhang L, Lublin DM.  Transfusion risks and trans fusion -related 
proinflammatory responses.  Hematol Oncol Clin North Am .  2007;21:147- 161.   
Doshi S, Chow A, Perez Ruixo JJ.  Exposure- response modeling of darbepoetin alfa in 
anemic patients with chronic kidney disease not receiving dialysis.  J Clin Phar macol .  
2010,50:75S -90S. 
Eder AF, Chambers LA.   Noninfectious complications of blood transfusion.   Arch Pathol 
Lab Med.  2007;131:708 -718. 
Egrie JC, Grant JR, Gillies DK, Aoki KF, Strickland TW.  The role of carbohydrate on the 
biological activity of erythropoietin [abstract].   Glycoconj J .  1993;10:263.  
Eschbach JW, Adamson JW.  Anemia of end- stage renal disease (ESRD).  Kidney Int .  
1985;28:1 -5. 
Gilbertson DT, Ebben JP, Foley RN , et al.  Hemoglobin level variability:  associations 
with mortality.  Clin J A m Soc Nephrol .  2008; 3:133 â€“138. 
Goodnough LT, Shander A.   Blood Management.  Arch Pathol Lab Med.  
2007;131:695 -701. 
Goldman M, Vanherweghem JL.   Multiple blood transfusions and iron overload in 
patients receiving haemodialysis.   Nephrol Dial Transplant .  1987;2:205 -207. 
Hill GS, Nochy D, Bruneval P, et al.  Donor -specific antibodies accelerate 
arteriosclerosis after kidney transplantation.  J Am Soc Nephrol .  2011;22:975-9 83.  
Holander M, Wolfe DA. Nonparametric Statistical Methods. [LOCATION_001]: Wiley; 
1973:67- 79. 
International Committee of Medical Journal Editors, Recommendations for the 
Conduct, Reporting, Editing and Publication of Scholarly Work in Medical 
Journals.   2013.  http://www.icmje.org/  
Kazmi WH, Kausz AT, Kahn S, et al.  Anemia:  An early complication of chronic renal 
insufficiency.  Am J Kidney Dis .  2001;38:803 -812. 
Lawler EV, Bradbury BD, Fonda JR, et al.  Transfusion burden among patients with 
chronic kidney disease and anemia.  Clin J Am  Soc.  2010;5:667- 672. 
Leo A, Pedal I.  Diagnostic approaches to acute transfusion reactions.   Forensic Sci Med 
Pathol .  2010;6:135-[ADDRESS_1160357]:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  16 December 2013  Page 59 of 67 
 Levin A, Thompson CR, Ethier J, et al.  Left ventricular mass index increase in early 
renal disease:  impact of decline in hemoglobin.  Am J Kidney Dis .  1999;34:125- 134. 
Macdougall I.  Novel erythropoiesis stimulating protein.  Sem Nephrol.   
2000;20:375 -381. 
Mann JFE.  What are the short -term and long -term consequences of anaemia in CRF 
patients?  Nephrol Dial Transplant .  1999;14[Suppl 2]:[ADDRESS_1160358], Jurkovitz C, Presley R.  Anemia and renal 
insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospi[INVESTIGATOR_600]:  A population- based study.  J Am Soc Nephrol .  
2002;13:1928 -1936.  
Moranne O, Froissart M, Rossert J , et al.  Timing of onset of CKD -related metabolic 
complications.  J Am Soc Nephrol.  2009;20:164 -171. 
Murphey CL,  Forsthuber TG.  Trends in HLA antibody screening and identification and 
their role in transplantation.  Expert Rev Clin Immunol.   2008; 4:391- 399. 
Opelz G, Collaborative Transplant Study.  Non-HLA transplantation immunity revealed 
by [CONTACT_835770].  Lancet .  2005;365:1570- 1576.  
Pfeffer MA, Burdmann EA, Chen C -Y, et al.  A trial of darbepoetin alfa in type 2 diabetes 
and chronic kidney disease.  N Engl J Med.   2009;361:2019 -2032.  
Pi[INVESTIGATOR_65528], Hall JE, Appel AJ, et al.  Recommendations for blood pressure 
measurements in humans and experimental animals. Part 1: Blood Pressure Measurement in Humans: A Statement  for Professionals From the Subcommittee of 
Professional and Public  Education of the American Heart Association Council on High 
Blood Pressure  Research.  Circulation .  2005 ;111:697- 716. 
Provenzano R, Garcia -Mayol L, Suchinda P, et al.  Once- weekly epoetin alfa for treating 
the anemia of chronic kidney disease.  Clin Nephrol.   2004;61:392 -405. 
Sarnak MJ, Tighiouart H, Manjunath G, et al.  Anemia as a risk factor for cardiovascular 
disease in The Atherosclerosis Risk in Communities (ARIC) study.  J Am Coll Ca rdiol.  
2002;40:27 -33. 
Seetharam A, Tiriveedhi V, Mohanakumar T.  Alloimmunity and autoimmunity in chronic 
rejection.  Curr Opin Organ Transplant.  2010;15:531- 536. 
Simon GE, Bove JR.  The potassium load from blood transfusion.  Postgrad Med.  
1971;49:61 -64. 
Singh AK, Szczech L, Tang KL, et al.  Correction of anemia with epoetin alfa in chronic 
kidney disease.  N Engl J Med.  2006;355:2085 -2098.  
Susal C, Dohler B, Sadeghi M, Ovens J, Opelz G .  HLA Antibodies and the Occurrence 
of Early Adverse Events in the Modern Era of Transplantation: A Collaborative 
Transplant Study Report.  Transplantation .  2009;87:1367â€“1371.  
Weinhandl ED, Peng Y, Gilbertson DT, Bradbury BD, Collins AJ .  Hemoglobin variability 
and mortality: confounding by [CONTACT_89309].  Am J Kidne y Dis .  2011;57:255- 265. 
 
 
  Product:  Dar bepoetin alfa  
Protocol Number:  20110226  
Date:  [ADDRESS_1160359]:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  16 December 2013  Page 61 of 67 
 Appendix A .  Schedule of Assessments 
Treatments and Procedures  Screening   Visit Frequency   
Visit 1  Visit 2 (g)  Day 1  Week 5  Q4W  Q2W (i)  Q12W  Q24W  EOS/ET  
Week 101  
General and Safety  Assessments  
Informed consent (a)  X         
Medical/surgical history , including history of transfusion s    X       
Physical exam and height (b)    X      X 
Electrocardiogram    X       
Blood pressure, pulse  X X  X X X   X 
Weight  X  X      X 
Concomi tant medications including iron, and commercial ESAs    X X X    X 
Concomitant medications  â€“ antihypertensive medications    X X X X   X 
RBC transfusions  and transfusions of other blood -derived products  (c)    Record continuously  
Endpoint data collection  for adjudication (c)    Record continuously  
Hospi[INVESTIGATOR_602], including observational stays, and emergency 
department visits (c)    Record continuously  
Adverse events/serious adverse events (d, e)                                 Record continuously  
Labora tory Assessments (f)  
eGFR, serum creatinine (h) X  X     X X 
Complete blood count (CBC)    X X   X   
Hb, using  modified  Hb point of care device  X X  X X    X 
TSAT, ferritin, iron, TIBC  X  X X   X   
Vitamin B12, folate  X         
Serum pregnancy test (all women of child bearing potential)  X         
Blood s amples for biomarkers    X     X X 
Anti-HLA antibodies    X    X  X 
Spot urine albumin and creatinine    X       
Troponin -T, serum albumin, high sensitivity CRP    X       
Reticulocytes    X       
Anti-erythropoietic protein antibodies    X      X 
Dosing  
Investigational product administration    X X X     
a) To occur before any study procedure                        f)  Samples should be drawn before investigational product administration   
b)  Rectal and gynecological not required                       g)  Eligible subjects must have Visit 2 and Day 1 completed on the same date   
c)  Record continuously throughout duration of study                      h)  eGFR and serum creatinine will not be performed on subjects who require renal replacement therapy   
d)  S erious adverse events collected from date of consent through 4 weeks after final dose of IP      i)  Required if SBP â‰¥ 160 mmHg during routine study visit, at investigator discretion if SBP < 160 mmHg  
(see Section 9.2.2 for) additional details   
Adverse events, collected  from Day [ADDRESS_1160360]:  Darbepoetin  alfa 
Protocol Number:  20110226  
Date:  [ADDRESS_1160361] Adverse Event Toxicity Grading Scale  
1 MILD:  Aware of sign or symptom, but easily tolerated  
2 MODERATE:  Discomfort enough to cause interference with usual activity  
3 SEVERE:  Incapacitating with inability to work or do usual activity  
4 LIFE -THREATENING:  Refers to an event in which the patient was, in the view of the 
investigator, at risk of death at the time of the event.  (This category is not to be used 
for an event that hypothetically might have caused death if it were more severe.)  
[ADDRESS_1160362]:  Darbepoetin  alfa 
Protocol Number:  20110226  
Date:  16 December 2013  Page 63 of 67 
 Appendix C .  Sample of the Serious Adverse Event Worksheet/electronic Serious 
Adverse Event (eSAE) Contingency Report Form  
 
 
  Product:  Darbepoetin  alfa 
Protocol Number:  20110226  
Date:  [ADDRESS_1160363]:  Darbepoetin  alfa 
Protocol Number:  20110226  
Date:  [ADDRESS_1160364]:  Darbepoetin  alfa 
Protocol Number:  20110226  
Date:  [ADDRESS_1160365]:  Darbepoetin  alfa 
Protocol Number:  20110226  
Date:  [ADDRESS_1160366]:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  16 December 2013  Page 1 of 9 
   Amendment 3 
Protocol Title:  START -CKD:  Strategies Using Darbepoetin alfa to Avoid 
Transfusions in Chronic Kidney Disease 
 
[COMPANY_010] Protocol Number (Darbepoetin alfa)  20110226 
 
Amendment Date:  16 December 2013  
Rationale:  
The purpose of this amendment is to address challenges with enrollment into the trial 
and potentially reduce the screen failure rate.   
The following eligibility criteria have been modified to have a positive impact on 
enrollment without a significant impact on the population being studied : 
â€¢ Removal of lower limit for eGFR required for inclusion 
â€¢ Modification of time required between events and screening  including : 
o Receipt of a red blood cell transfusion 
o Occurrence of:  
ï‚§ Seizure  
ï‚§ Clinically relevant active bleeding  
ï‚§ Hospi[INVESTIGATOR_059]  
ï‚§ Receipt of erythropoiesis stimulating agents  
Minor administrative changes and clarifications have also been incorporated.  
Additions are noted in bold  text.  
 
  Product:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  16 December 2013  Page 2 of 9 
   Description of Changes:  
Section: Global  
Replace date of protocol : 
25 June 2013  
With:  
16 December  2013  
Section:  Global  
Replace:  
Investigational Hb point of care (POC) device 
With:  
Modified  Hb point of care (POC)  device 
Page 1, Title Page   
Add: 
Amendment [ADDRESS_1160367]:   
â€¢ Estimated glomerular filtration rate of â‰¥ 15 to < 45 ml/min/1.73m2 
With:  
â€¢ Not currently receiving dialysis with an estimated glomerular filtration rate of 
< 45.0 mL/min/1.73m2 during screening  
Page 5, Synopsis  
Replace:  
â€¢ Received erythropoiesis stimulating agents (ESAs) within 12 weeks of screening 
â€¢ Received an RBC transfusion within 12 week s of screening 
With:  
â€¢ Received erythropoiesis stimulating agents (ESAs) within 4 weeks of screening 
â€¢ Received an RBC transfusion within [ADDRESS_1160368]:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  16 December 2013  Page 3 of 9 
   Page 6, Synopsis  
Add: 
Subjects ending investigational product prior to week [ADDRESS_1160369]:  
4.1.3  eGFR â‰¥ 15.0 and < 45.0 mL/min/1.73m2, per the central laboratory during 
screening  
With:  
4.1.3  Not currently receiving dialysis with an eGFR < 45.0 mL/min/1.73m2, per the 
central laboratory during screening  
Page 22, Section 4.2, Exclusion Criteria  
Replace:  
4.2.6  Currently receiving systemic antibiotics for treatment of an active infection 
With:  
4.2.[ADDRESS_1160370]:  
Within 12 weeks of screening  
4.2.17  Receipt of any of the following: 
â€¢ RBC Transfusion  
â€¢ ESA Therapy  
With: 
Within 8 weeks of screening  
4.2.17  Receipt of any of the following: 
â€¢ RBC Transfusion  
 
  Product:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  [ADDRESS_1160371]:  
Within 4 weeks of screening  
4.2.19  Receipt of any intravenous (IV) iron therapy  
4.2.20  Changes in oral iron therapy  
4.2.21  Any outpatient surgery  
With: 
Within 4 weeks of screening  
4.2.19  Receipt of any intravenous (IV) iron therapy  
4.2.[ADDRESS_1160372]:  
Subjects who fail screening may be rescreened as described in Section 7.1.[ADDRESS_1160373] screening procedure. 
With:  
Subjects who fail screening may be rescreened as described in Section 7.1.[ADDRESS_1160374]:  
The medical devices that are provided by [CONTACT_835752]:  A 
modified HemoCue Hb 201+ system hemoglobin analyzer (investigational) and an Omron HEM 705 CP Auto Inflate Blood Pressure Monitor (commercially available).   
With:  
The medical devices that are provided by [CONTACT_835752]:  A 
modified HemoCue Hb 201+ system hemoglobin analyzer and an auto inflate Blood 
Pressure Monitor.  
 
  Product:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  16 December 2013  Page 5 of 9 
   Page 27, Section [IP_ADDRESS], Dosage Adjustments Based on Systolic Blood Press ure 
Values  
Replace:  
If the subjectâ€™s mean SBP is â‰¥ 160 mmHg for three consecutive visits (including blood 
pressure monitoring visits), the dose of investigational product will be withheld.  
With:  
If the subjectâ€™s mean SBP is â‰¥ 160 mmHg for two consecutive visits (including blood 
pressure monitoring visits ), the dose of investigational product will be withheld.  
Page 29, Section 6.6, Medical Devices  
Replace:  
6.6 Investigational Medical Devices 
The following investigational medical devices will be used in this study and provided by 
[CONTACT_11337]:  
â€¢ Modified HemoCue Hb 201+ system hemoglobin analyzer  
With:  
6.6 Medical Devices  
The following medical devices will be used in this study and provided by [CONTACT_11337]:  
â€¢ Modified HemoCue Hb 201+ system hemoglobin analyzer  
â€¢ Auto inflate blood pressure monitor  
Page 29, Section 6.6.1 , Modified HemoCue Hb 201+ System Hemoglobin Analyzer  
Replace:  
The modified HemoCue is an investigational device provided by [CONTACT_835771].  
With:  
The modified HemoCue will be  provided by [CONTACT_835772]. 
 
  Product:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  [ADDRESS_1160375]:  
6.7 Other Medical Devices Provided 
[COMPANY_010] will also provide the Omron HEM 705 CP Auto inflate blood pressure monit or to 
be used throughout the trial for protocol specified blood pressure measurements.  The 
blood pressure will be measured as described in section 7.2.4.  
With:  
6.6.2  Other Medical Devices Provided 
[COMPANY_010] will also provide an auto  inflate blood pressure monitor to be used throughout 
the trial for protocol specified blood pressure measurements.  The blood pressure will be measured as described in section 7.2.4.  
Additional details for the automated blood pressure monitor may be found in the user manual that accompanies the device.  
Page 30, Section 6.7.1, Omron HEM 705 CP Auto Inflate Blood Pressure Monitor  
Remove:  
6.7.[ADDRESS_1160376]â€™s source documents.  
Additional details for the Omron automated blood pressure monitor may be found in the user manual that accompanies the device.  
Page 32, Section 7.1.2, Rescreening Evaluations  
Replace:  
Subjects who do not meet eligibility criteria during the initial screening attempt will be permitted to rescreen twice, for a total of 3 screening attempts.  
With:  
Subjects who do not meet eligibility criteria during the initial screening attempt will be 
permitted to rescreen [ADDRESS_1160377]:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  [ADDRESS_1160378]:  
At a minimum, subjects must be followed for the collection of RBC transfusions and 
endpoint data for adjudication.  In addition, serum for anti -erythropoietic protein antibody 
testing will be collected at the scheduled visit that occurs closest to the receipt of the last 
dose of investigational product.   
With:  
At a minimum, subjects must be followed for the collection of RBC transfusions and 
endpoint data for adjudication.  Refer to Section 8.[ADDRESS_1160379]:  
An adverse device effect is any adverse event related to the use of an investigational  
medical device.  Adverse device effects include adverse events resulting from insufficient or inadequate instructions for use, adverse events resulting from any malfunction of the investigational device(s), or adverse events resulting from use error or 
from intentional misuse of the investigational device(s)  
With:  
An adverse device effect is any adverse event related to the use of a medical device.  Adverse device effects include adverse events resulting from insufficient or inadequate instructions for use, adverse events resulting from any malfunction of the device(s), or 
adverse events resulting from use error or from intentional misuse of the device(s)  
Page 42, Section 9.1.2, Reporting Procedures for Adverse Events  
Replace:  
The investigator must assess whether the adverse event is possibly related to the 
investigational device.   This relationship is indicated by a â€œyesâ€ or â€œnoâ€ response to t he 
question:  Is there a reasonable possibility that the event may have been caused by [CONTACT_541592]? 
 
  Product:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  16 December 2013  Page 8 of 9 
   With:  
The investigator must assess whether the adverse event is possibly related to a device.   
This relationship is indicated by a â€œyesâ€ or â€œ noâ€ response to the question:  Is there a 
reasonable possibility that the event may have been caused by a device? 
Page [ADDRESS_1160380]:  
Authorship of any publications resulting from this study will be determined on the basis 
of the Uniform Requirement for Manuscripts Submitted to Biomedical Journals 
(International Committee of Medical Journal Editors) which states:  
With:  
Authorship of any publications resulting from this study will be determined on the basis 
of the International  Committee of Medical Journal Editors (ICMJE) 
Recommendations for the Conduct, Reporting, Editing, and Publication of 
Scholarly Work in Medical Journals which states:  
Page [ADDRESS_1160381]:  
â€¢ Authorship credit should be based on (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the 
article or revising it critically for important intellectual content; (3) final approval of the 
version to be published.  A uthors should meet conditions 1, 2, and 3. 
With:  
â€¢ Authorship credit should be based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the 
article or revising it critically fo r important intellectual content; (3) final approval of the 
version to be published; (4) and agreement to be accountable for all aspects of 
the work in ensuring that questions related to the accuracy or integrity of any 
part of the work are appropriately investigated and resolved.  Authors should meet conditions 1, 2, 3, and 4. 
Page 58, Section 13, References  
Replace:  
International Committee of Medical Journal Editors, Uniform Requirements for Manuscripts  Submitted to Biomedical Journals:  Writing and Editing for Biomedical 
Publication.  2006.  
http://www.icmje.org/  
 
  Product:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  16 December 2013  Page 9 of 9 
   With:  
International Committee of Medical Journal Editors, Recommendations for the 
Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical 
Journals.  2013.  http://www.ismje.org/  
 
 
  Product:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  25 June 2013  Page 1 of 2 
 Amendment 2 
Protocol Title:  START -CKD:  Strategies Using Darbepoetin alfa to Avoid 
Transfusions in Chronic Kidney Disease 
 
[COMPANY_010] Protocol Number (Darbepoetin alfa)  20110226 
 
Amendment Date:  25 June 2013  
 
Rationale:  
The purpose of this amendment is to further limit the potential for subjects with elevated 
blood pressure to be exposed to investigational product in the START- CKD study. 
Therefore, the exclusion criteria for uncontrolled hypertension has been modified.  
 
Additions are noted in bold  text.  
 
 
  Product:  Darbepoetin alfa 
Protocol Number:  20110226  
Date:  03 April 2013  Page 1 of 18 
   Amendment 1 
Protocol Title:  START -CKD:  Strategies Using Darbepoetin alfa to Avoid 
Transfusions in Chronic Kidney Disease 
 
[COMPANY_010] Protocol Number (Darbepoetin alfa)  20110226 
 
Amendment Date:  03 April 2013  
 
Rationale:  
The key purpose of this amendment is to  provide additional measures to improve blood 
pressure control in subjects enrolled in the START -CKD study who are receiving 
investigational product .  
The following changes have been made throughout the protocol:   
â€¢ The protocol eligibility criteria have been  modified and subjects with a mean systolic 
blood pressure > 140 mmHg or a mean diastolic blood pressure > 9 0 mmHg  at both 
screening visits will be excluded  
â€¢ Additional visits have been added for subjects with elevated blood pressures.  These 
blood pressu re monitoring visits will be required for subjects with a mean systolic 
blood pressure â‰¥ 160mmHg and may be conducted at the investigators discretion for 
those whose mean systolic blood pressure is < 160 mmHg    
â€¢ The dosing algorithm has been modified such that  investigational produc t will be 
withheld if a subjectâ€™s  mean systolic blood pressure is â‰¥ 160 mmHg for 3 consecutive 
visits (including blood pressure monitoring visits) and restarted only when the mean 
systolic blood pressure is â‰¤ 140 mmHg  
â€¢ Additional information regarding antihypertensive medication use will be collected at 
each study visit  
â€¢ Additional information regarding the investigational hemoglobin point of care device 
for the collection of study specific hemoglobin concentrations and the automated 
blood pressure monitor for the collection of blood pressure measurements has been 
provided. Both of these devices are provided by [CONTACT_835773].  
Additional clarifications and administrative changes h ave also been made.   
Additions are noted in bold  text.  
 